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ABSTRACT 
 Histamine and serotonin are important biogenic amines that regulate vital brain 
functions. These two transmitters are thoughts to be involved in neurodegenerative 
diseases such as Parkinson’s and Alzheimer’s and affective disorders including 
depression. Histamine and serotonin are believed to regulate each other but their 
fundamental neuromodulation mechanisms are not well understood. This lack of 
understanding makes brain disorders implicating these two transmitters difficult to 
diagnose and treat. Our lab extensively investigates the serotonergic system to understand 
serotonin’s neurochemistry in the brain. However, histamine is relatively understudied 
with respect to other biogenic amines because of an absence of suitable analytical tools. 
This work introduces a strategic approach to overcome this analytical challenge and 
investigates the real-time neuromodulation of in vivo histamine and serotonin to 
understand physiological functions in healthy and disease states using fast-scan cyclic 
voltammetry (FSCV). First, we perform a proof-of-principle study of Copper (Cu(II)) 
analysis to characterize the adsorption driven FSCV response. Next, we employ FSCV to 
develop a novel voltammetric method to selectively and sensitively monitor real-time in 
vivo histamine and serotonin neurotransmissions in the posterior hypothalamus (PH). 
This study reveals that histamine inhibits serotonin via an H3 receptor mediated process, 
highlighting histamine’s roles in regulating serotonin release in the brain. Following that, 
we examine histamine’s reuptake mechanisms via monoamine transporter proteins and 
demonstrate that histamine uptake mechanism is mediated by organic cation transporters. 
viii 
Finally, we use our novel FSCV method to monitor histamine and serotonin 
neurotransmissions in HIV- 1 Tg rats, which exhibit neuroinflammation, to understand 
impaired neurochemical mechanisms in the disease state. Collectively, this dissertation 
showcases a novel and robust electroanalytical strategy to simultaneously monitor in 
vivo histamine and serotonin neuromodulation in real time. Innovative discoveries in this 
systematic investigation of the histaminergic regulation of serotonin in diverse 
neurochemical and pathophysiological processes will pave the way towards more 
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1.1 Neuromodulation of Histamine and Serotonin 
Histamine is an important biogenic amine which modulates vital brain functions1-3 
by regulating other neurotransmitters, in particular serotonin4,5. These two chemical 
messengers co-exist in multiple brain regions6,7 and are implicated in many brain 
dysfunctions such as Parkinson’s8-10 and Alzheimer’s diseases11,12 and mood 
disorders13,14. Lack of knowledge regarding histamine and serotonin neuromodulation 
mechanisms makes such brain disorders hard to diagnose and cure. Our lab widely 
investigates the serotonergic system to understand the complex neurochemistry of this 
molecule using electroanalytical tools15,16. However, histamine neurochemistry has been 
relatively understudied with respect to serotonin. It is desirable, therefore, to study in vivo 
neuromodulation of these two neurotransmitters to understand their functions in healthy 
and disease states. To date, this topic has been challenging due to the absence of 
appropriate analytical tools. This dissertation illustrates the development of a novel 
voltammetric method to monitor, in real-time, the modulatory profile of these two 
messengers. The serotonergic and histaminergic systems are discussed in the first part of 
this chapter. The second portion describes existing electroanalytical techniques to 
monitor in vivo neurotransmissions, while the latter part of the chapter focuses on method 
development toward in vivo histamine-serotonin detection. 
 
2 
1.1.1 The Serotonergic System 
Serotonin is a vital neurotransmitter that is implicated in mood and emotional 
brain functions17. Dysregulation of this chemical messenger in the brain causes several 
neurological disorders such as anxiety and depression13,14. Therefore, serotonin has been 
the main focus of depression and antidepressant drug related studies13. However, the tight 
regulation of in vivo serotonin in the brain creates limitations for analytical tools to 
monitor rapid serotonin neurotransmissions. Despite limited selectivity, differential pulse 
voltammetry and chronoamperometry studies have brought forth noteworthy information 
about in vivo serotonin dynamics18,19. In 2009 Hashemi et al. employed fast-scan cyclic 
voltammetry (FSCV) to detect in vivo stimulated serotonin release in the rat substantia 
nigra pars reticulate (SNr) as a more selective and robust method20. 
With this method, our lab primarily concentrates on in vivo serotonin 
neurotransmission in depression and autism spectrum disorder. The Hashemi lab has been 
studying endogenous serotonin release and reuptake mechanisms using FSCV. For 
instance, our lab confirmed that the serotonin system consists of two distinct reuptake 
mechanisms and found a prolonged inhibitory role for serotonin autoreceptors16. 
Histamine has been previously thought to modulate serotonin4. Therefore, I became 
interested in investigating histamine and serotonin neuromodulation. More details about 
the histaminergic system are presented in the next section.            
1.1.2 The Histaminergic System 
Histamine is a monoamine neurotransmitter which regulates important brain 
functions such as circadian rhythm and inflammation3. Histamine is synthesized from the 
 
3 
amino acid histidine via decarboxylation by the histidine decarboxylase enzyme21. 
Neuronal histamine is stored in cell somas and neuroeffector junctions22,23. Like other 
biogenic amines, this transmitter is packaged into vesicles by vesicular monoamine 
transporters and released upon the action potential activation24. However unlike other 
biogenic amines, there is no known active transport mechanism for histamine25,26. 
Therefore, enzymatic degradation is thoughts to be the primary means of histamine 
inactivation via the N-methyltransferase enzyme27,28. Tele-methylhistamine, the product 
of the histamine degradation, undergoes further degradation to t-methyl-imidazoleacetic 
acid via monoamine oxidase29.  
Past studies have identified four histamine receptors, namely the H1, H2, H3, and 
H4 receptors. All receptors are rhodopsin-like G-protein coupled receptors
3. Histamine 
neurons are excited through H1 receptor activation and H1 receptor dysfunction leads to 
immunological and behavioral abnormalities30. H1 receptor antihistaminergic agents 
inactivate the H1 receptors and break signal propagation
31. Distribution of the H2 
receptors is more consistent and widespread in the rodent brain32. Dysregulation of this 
receptor is associated with cognitive impairments33. Activation of the H3 autoreceptor, 
which is an inhibitory feedback receptor on the presynaptic histamine neuron, inhibits 
histamine release and synthesis34,35. Additionally, this presynaptic receptor controls the 
release of other neurotransmitters, including glutamate, acetylcholine, and serotonin3,25. 
Loss of H3 receptor function is related to abnormalities in locomotion, behavior, and 
weight36,37. H4 receptors exhibit properties similar to the H3 receptors but are expressed in 
the peripheral system38.  
 
4 
Recent studies have shown that irregularities of the histaminergic system cause 
abnormalities in neuroendocrine and higher brain functions. Histamine levels are 
significantly increased in the brains of Parkinson’s patients8,10. The degeneration of 
histaminergic fibers in the tuberomammillary nucleus (TMN), as well as globally lowered 
neuronal histamine levels, are well-documented in Alzheimer’s disease11. Moreover, 
histamine is a key biomarker of inflammation which is comorbid with many brain 
disorders39,40. Also, a recent study has illustrated that histamine may promote anxiety, 
while lesions of the TMN reduce symptoms41. Interestingly, histamine neurons in TMN 
are related to neuroendocrine signals concerned with mood disorders like depression33,42. 
This relationship between histamine and depression is appealing to our lab since we 
primarily concentrate on serotonin, which is the transmitter most highly implicated in 
depression and anxiety. 
Therefore, I find it of great significance to direct my efforts to study in vivo 
histamine and serotonin modulation. However, studying this neuromodulation 
mechanism has been challenging due to the absence of suitable analytical techniques, 
which can simultaneously monitor these two chemical messengers in vivo. An ideal 
method should encompass: sensitivity for low neurotransmitter concentrations, selectivity 
for different neurotransmitters, adequate speed for monitoring sub-second 
neurotransmission and appropriate probes for real-time in vivo measurements. 
Electroanalytical techniques and how they address these challenges are described in the 




1.1.3 Detection and Quantification of Neurotransmitters 
Monitoring the brain’s chemicals and neurotransmitters necessitates specific 
requirements. First, brain signaling events occur on a sub-second time scale. Thus, the 
temporal resolution of the method should be sufficient to monitor these events. Secondly, 
the brain is physically delicate thus the technique should be minimally invasive. Third, 
neurotransmitters and their metabolites are chemically similar, which means the tool must 
have a high degree of selectivity to distinguish between species. Lastly, neurotransmitters 
are present at very low concentrations in the synapse. Accordingly, an ideal detection 
method must display excellent sensitivity. 
Carbon fiber microelectrodes (CFMs) are biocompatible, robust, stable, and cause 
minimal damage to the brain tissue. They also have favorable and fast surface kinetics for 
sensitive measurements43. Moreover, the large surface area due to the rough exterior of 
the carbon surface allows for more adsorption as shown in Figure 1.1. Undoubtedly, 
combining CFMs with electroanalytical techniques permits the quantification of 













1.1.4 CFMs and Electroanalytical Techniques 
Some monoamine, like dopamine, serotonin, histamine and adenosine, are 
electroactive. Therefore, the dynamics of these electroactive messengers can be studied 
using electroanalytical techniques in vivo as described below.  
Amperometry works by holding the CFM at a potential that is more positive than 
the analyte’s oxidation potential.  The resulting continuous oxidation produces a current 
which is used to quantify the neurotransmitters around the electrode. This method has 
been developed to monitor exocytosis in a single cell44. Moreover, the flexibility of 
CFMs makes it feasible to build microelectrode arrays. For instance, the Ewing group has 
been using a 16-electrode array to monitor exocytosis from a single cell45. Amperometry 
is a sophisticated technique to measure chemical messengers. However, selectivity is 
inadequate for monitoring neurotransmission in complex media, because the constant 
potential oxidizes all electroactive analytes below the applied potential. 
Chronoamperometry has been developed to overcome the selectivity problem 
with amperometry. This method uses a square wave (between defined potential limits) to 
CFMs at 5-25 Hz. The square wave generates a large capacitative current at the step 
functions, which decays exponentially over time. Chronoamperometry can provide the 
selectivity required, to some degree, by taking a ratio of oxidative and reductive currents. 
This method has been using to study Parkinson’s disease46, depression47, addiction48, and 
transporter kinetics49. Collectively, chronoamperometry can successfully monitor 
neurotransmitter clearance, although more selectivity is required to monitor various 
 
7 
neurotransmissions in vivo. The next section describes FSCV as a robust and selective 
electrochemical technique to monitor real-time in vivo neurotransmission. 
1.2 Fast-Scan Cyclic Voltammetry (FSCV) 
Julian Milar and colleagues first presented FSCV to detect electroactive 
neurotransmitters in the mid-20th century50. Over several decades, FSCV has been 
emerging as an electroanalytical technique on diverse frontiers. Primarily, FSCV has 
been utilized to monitor real-time dopamine dynamics51,52. Our lab has pioneered the 
application of FSCV to serotonin, histamine53, Cu(II)54 and Pb(II)55. FSCV employs high 
scan rates (100 Vs-1 to 1500 Vs-1) at a frequency of 10 Hz, whereas traditional cyclic 
voltammetry uses mVs-1 scan rates. Therefore, with the higher scan rates employed in 
FSCV, a single data set is collected within milliseconds, which raises the temporal 
resolution to the sub-second scale. However, high scan rates also produce large non-
faradaic currents at the electrode surface, which mask the faradaic signal. Therefore, 
FSCV is modified to integrate background subtraction to remove this non-faradaic signal. 
As a result of background subtraction, FSCV can only detect changes. Therefore, 
stimulation is used to evoke neurotransmitter release in vivo.        
In FSCV, the CFM is held at a resting potential between cycles, allowing 
neurotransmitters to adsorb onto the carbon surface. During the anodic wave, which 
ramps up from the resting potential to a positive potential limit, adsorbed analytes will be 
oxidized on the electrode surface; likewise, during the cathodic wave analytes will be 
reduced. This potential vs. time instruction is known as a FSCV waveform and the 
resulting faradaic events generate electron flow through the electrode, measurable as a 
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current. After background subtraction, FSCV generates an analyte specific cyclic 
voltammogram (CV), that can be used for qualitative and quantitative analysis. For data 
interpretation purposes, a 2D plot, also known as color-plot, is digitally constructed by 
stacking a set of CVs collected at 10 Hz for a limited time of period. Quantitative data 
along the time axis is provided by extracting horizontal data points along the event. 
Serotonin detection is challenging with FSCV because serotonin’s metabolites 
foul the electrode surface. However, a thin coating of Nafion, a cation exchange polymer, 
overcomes this fouling issue20. Figure 1.2 illustrates the stimulated release of serotonin 
in the CA2 region of the hippocampus medial forebrain bundle (MFB) stimulation. 
Figure 1.2A shows a representative data color plot. The discrete green event around 0.7 
V demonstrates serotonin oxidation. A typical serotonin CV is presented inset in the color 
plot. Figure 1.2B represents [serotonin] vs. time event upon stimulation. 
Figure 1.2. The stimulated release of serotonin in mouse hippocampus CA2. (A) 
representative color plot. Inset shows a classic serotonin CV extracted from the vertical 
white dashed line. (B) illustrates a [serotonin] vs. time response obtained from the 




1.2.1 Expanding the Scope of FSCV 
Histamine56, adenosine57 and H2O2
58 have similar CVs because their oxidation 
peaks appear on the cathodic wave. Thus, their identities have only been tested via 
pharmacological approaches. Modification of the FSCV waveform can permit these 
neurotransmitters to be monitored more selectively without pharmacological verification. 
Developing a FSCV method to monitor several neurotransmitters simultaneously is 
challenging but would provide critical information about their modulatory mechanisms in 
the brain. 
Figure 1.3. (A) Representative color plot for simultaneous detection of histamine and 
serotonin in mouse posterior hypothalamus. (B) CV extracted from the vertical white 
dashed line at the histamine event. (C) [histamine] and [serotonin] vs. time obtained from 
horizontal dashed line along both events. The blue bar right underneath the color plot and 
in (C) represents the stimulation. 
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Figure 1.3A illustrates a representative color plot for simultaneous detection of 
histamine and serotonin in mouse posterior hypothalamus (PH). I developed this novel 
FSCV waveform that detects both the oxidation of histamine and serotonin 
simultaneously53,59. FSCV recognizes histamine releases (green event), which is denoted 
by white horizontal dashed line labeled “histamine”, in PH upon stimulation of the MFB 
as shown in the Figure 1.2A. A subsequent serotonin event appears (blue event right 
above histamine event) with a slight delay as denoted by a white dashed line labeled 
“serotonin” in the color plot. Figure 1.2B represents the unique CV that is extracted from 
the vertical dashed line along the events, and histamine oxidation appears around 0.3 V 
whereas inverse serotonin oxidation occurs around 0.8 V. This inverse oxidation 
(negative event) illustrates the reduction of ambient serotonin concentration after the 
stimulation. Figure 1.1C shows [histamine] and [serotonin] vs. time responses obtained 
from the horizontal dashed lines along both events in the color plot and these traces 
demonstrate real-time histaminergic modulation of serotonin. This novel method can be 
used to investigate in vivo histamine and serotonin to define their roles in healthy and 
pathophysiological states.   
This dissertation presents a systemic approach to developing a novel 
electrochemical tool for simultaneous detection of in vivo histamine and serotonin, as 
described below. 
1.3  Scope of the Dissertation 
In this dissertation, I first used Cu(II) metal analysis to understand the adsorption 
driven FSCV response (Chapter 2). Using that knowledge, I then developed a novel 
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FSCV method to selectively and sensitively monitor histamine neurotransmission in the 
mouse posterior hypothalamus (Chapter 3). This work was extended to simultaneously 
monitor histamine and serotonin in real time to study their neuromodulation in the brain 
(Chapter 4). Since an active reuptake mechanism for histamine has not been identified, I 
then utilized our novel method to study histamine reuptake mechanisms via monoamine 
transporter proteins (Chapter 5). Finally, I used our novel FSCV method to investigate 
histaminergic regulation of serotonin during disease using HIV-1 Tg rats which exhibit 
neuroinflammation (Chapter 7).  The outline of this dissertation is described below. 
Chapter 1: Introduction 
Chapter 2:  This chapter describes the underlying fundamental mechanism of adsorption 
driven FSCV responses. We demonstrated the progression of the FSCV response from 
the classical cyclic voltammetry response using the Cu(II) analysis. Finally, we proved 
that adsorption of Cu(II) onto the CFM surface follows a Langmuir adsorption isotherm.   
Chapter 3:  In this chapter, we optimized an electrochemical waveform that provided a 
stimulation-locked and unique electrochemical signal for histamine. Then, we described 
in vitro waveform optimization and in vivo detection of the stimulated release of 
histamine in the mouse PH via electrical stimulation in the MFB. Finally, this chapter 
demonstrated that a robust signal can be used to describe histamine's in vivo dynamics. 
Chapter 4: This chapter describes a voltammetric approach to simultaneous monitoring 
of histamine and serotonin in real time. We found that serotonin was rapidly and potently 
inhibited by histamine release in a concentration-dependent manner. Lastly, we 
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developed mathematical models and performed pharmacological experiments to verify 
that this serotonin inhibition was mediated by H3 receptors.  
Chapter 5: In this section, we employed a previously described FSCV method (chapter 
4) to investigate histamine reuptake kinetics pharmacologically. Moreover, this section 
provides evidence for organic cation transporter mediated histamine uptake. We also 
found that histamine reuptake mechanism were inhibited by commercially available 
antidepressant drugs: escitalopram, citalopram, and desipramine.  
Chapter 6: This chapter illustrates fundamental neurochemical changes in serotonin and 
histamine in HIV-1 Tg rats, which display neuroinflammation. We employed FSCV to 
interpret impaired neurotransmissions and found that histamine release was elevated in 
HIV-1 Tg rats which in turn inhibited more serotonin compared to the control animals.   
Chapter 7:  The final chapter summarizes the conclusions of this research work and 
highlights the future directions. 
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Rapid, in situ trace metal analysis is essential for understanding many biological 
and environmental processes. For example, trace metals are thought to act as chemical 
messengers in the brain. In the environment, some of the most damaging pollution occurs 
when metals are rapidly mobilized and transported during hydrologic events (storms). 
Electrochemistry is attractive for in situ analysis, primarily because electrodes are 
compact, cheap and portable. Electrochemical techniques, however, do not traditionally 
report trace metals in real-time. In this work, we investigated the fundamental 
mechanisms of a novel method, based on fast-scan cyclic voltammetry (FSCV), that 
reports trace metals with sub-second temporal resolution at carbon-fiber microelectrodes 
(CFMs). Electrochemical methods and geochemical models were employed to find that 
activated CFMs rapidly adsorb copper, a phenomenon that greatly advances the temporal 
capabilities of electrochemistry.  We established the thermodynamics of surface copper 
adsorption and the electrochemical nature of copper deposition onto CFMs and hence 
identified a unique adsorption-controlled electrochemical mechanism for ultra-fast trace 
metal analysis. This knowledge can be exploited in the future to increase the sensitivity 
and selectivity of CFMs for fast voltammetry of trace metals in a variety of biological 
and environmental models.  
2.2 Introduction 
Trace metal analysis in real-time is essential for understanding many biological 
and environmental processes. For example, trace metals have important functions in 
biology and are garnering new attention for their roles as neurotransmitters1,2. In 
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Alzheimer’s disease for example, copper accumulates in -amyloid plaques3. It is thought 
that this copper build-up comes at the expense of its normal roles as a neurotransmitter, 
accounting for some of the disease’s neurological deficits3,4. It has been impossible to 
chemically monitor endogenously acting copper to verify this hypothesis, primarily 
because chemical transmission occurs so quickly (< seconds). 
Rapid metal analysis is also important in the environment, particularly in natural 
water systems where trace metal contamination is extremely hazardous5. The well-
documented health consequences of trace metal exposure6-9 are exacerbated because 
metals bioaccumulate in plants and animals10-13, providing numerous exposure paradigms 
for humans. Anthropogenic sources of trace metals are commonly mobilized and 
transported during hydraulic events (storms)14. It is critical to characterize aquatic trace 
metals in real-time because their interactions with organic ligands and soils are fast (< 
seconds)15. Such rapid metal detection would provide the most efficient implementation 
of existing metal mitigation systems 16-21 via a diagnostic approach. 
Most analytical techniques cannot monitor metals rapidly (< seconds). 
Spectroscopic techniques are sensitive and selective22, however sample collection and 
preparation can alter metal speciation and make dynamic measurements difficult23,24. 
Electrochemical methods are attractive because the chemistry occurs at a submersible or 
integrated surface that minimally impacts its surroundings. Ion-selective electrodes have 
a temporal resolution of seconds;25,26 however it is typically challenging to make 
measurements in dynamically changing matrices. Stripping voltammetries (such as 
anodic stripping and adsorptive stripping voltammetry) have extremely high 
sensitivities27. This high sensitivity is largely due to a lengthy pre-concentration step 
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(minutes) that decreases temporal resolution28-30. Moreover, anodic stripping 
voltammetry is most commonly performed at Hg electrodes31 which have limited 
portability and pose their own toxicity concerns. 
We recently described the use of carbon-fiber microelectrodes (CFMs) to detect 
copper (II) (Cu2+) and lead (II) (Pb2+) with fast scan cyclic voltammetry (FSCV) at scan 
rates of 300 – 600 Vs-1 32,33. Our ultra-fast, Hg-free method can quantify Cu2+ and Pb2+ 
concentration changes every 100 ms with parts per billion and parts per million 
sensitivity, respectively32,33. Our method is highly applicable for studying metals in real 
time. However it is essential to describe the fundamental mechanisms of this fast 
voltammetric method before it can be developed into a routine analytical tool for 
biological and environmental applications. In this paper therefore, we take a multi-
faceted approach and establish the underlying mechanisms of fast voltammetry of Cu2+ 
on CFMs in established laboratory test solutions.  
We analyzed Cu2+, a biologically relevant2 and environmentally problematic 
metal ion34 with well-known redox chemistry35,36. Besides classical nucleation, growth 
and stripping features36, we observed new, additional  peaks in Cu2+ slow scan cyclic 
voltammograms. These additional peaks were not diminished, as the classical features 
were, when the scan-rate was increased. In fact, with increasing scan rate, the new 
features were augmented, as seen previously with neurotransmitters adsorbed to CFM 
surfaces37. We therefore investigated surface adsorption as a fundamental mechanism of 
the Cu2+ FSCV signal. We utilized electrochemical, geochemical, and microscopic tools 
to describe CFM’s surface and thermodynamic mechanisms towards Cu2+. This study 
provides valuable insight into the adsorption chemistry that governs the FSCV response 
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to metals. Our findings are critical to the future development of the method, namely 
increases in sensitivity and selectivity, in application to real samples. 
2.3 Experimental Section 
2.3.1 Solutions 
Cu2+ solutions were prepared by dissolving Cu(NO3)2 in NaCl (0.01 M) and in tris 
buffer (15 mM tris(hydroxymethyl)aminomethane), 140 mM NaCl, 3.25 mM KCl, 1.2 
mM CaCl2, 1.25 mM NaH2PO4, 1.2 mM MgCl2 and 2.0 mM Na2SO4). All chemicals 
were purchased from Sigma-Aldrich (St. Louis, MO). At room temperature and pressure, 
the pH of Cu2+ in NaCl and tris buffer solutions was ~5.5 and 7.4 respectively. 
2.3.2 Microelectrodes 
CFMs were prepared by vacuum aspirating a single carbon fiber of 5 µm radius 
(T-650, Cytec Industries, NJ) into a glass capillary (0.6 mm external diameter, 0.4 mm 
internal diameter, A-M Systems, Inc., Sequim, WA).  The capillary was pulled under 
gravity with a micropipette puller (Narishige, Tokyo, Japan) leaving a tapered end to 
form a carbon-glass seal.  The exposed end of the carbon fiber was cut to approximately 
150 µm under a microscope. Gold microelectrodes (AuMs) were prepared as described 
above but with a gold microwire of 10 µm radius (Goodfellow Co, PA), cut to 
approximately 150-200 µm. 
2.3.3 Cyclic Voltammetry 
All voltammetry employed a 2-electrode system. Cyclic voltammograms were 
collected on 5 different electrodes and representative examples are displayed. For slow 
scan cyclic voltammetry (scan rates ≤ 100 mVs-1), microelectrodes were placed into a 
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constantly stirred solution of Cu(NO3)2 and a triangular wave form (+1 V to –1 V) was 
applied using custom software, Wildcat CV, written in LAB-VIEW 2012 (National 
Instruments, Austin, TX). Only solutions for slow scan cyclic voltammetry were 
nitrogen-purged prior to experimentation. The reference electrode was fabricated by 
electroplating Cl– on a Ag wire (A-M systems, WA). For scan rates above 1 Vs-1, in-
house software, WCCV 2.0, written in LABVIEW 2012 collected background-subtracted 
voltammograms in a flow-injection analysis system.  
2.3.4 Electrochemical Pre-treatment 
For most experiments microelectrodes were electrochemically pre-treated with a 
Cu2+ sensitive triangular waveform as previously described.33 For experiments comparing 
electrochemical and chemical pretreatments, the anodic potential/rest potential of the 
CFMs was varied from +0.4 V to +1.3 V at a constant cathodic potential of -1.0 V at a 
scan rate of 300 Vs-1. Electrodes were treated with each waveform for 10 minutes at 60 
Hz and then 10 minutes at 10 Hz.  
2.3.5 Chemical Pre-treatment 
CFMs were chemically pretreated with a mixture of H2SO4 (0.25 M) and HNO3 
(0.25 M) in a 3:1 ratio38 and washed with DI water prior to analysis.  
2.3.6 Solution Geochemistry 
Solution chemistry of Cu2+ in tris buffer and NaCl was modeled using 
PHREEQCi, a geochemical modeling software capable of determining speciation based 
on thermodynamic equilibrium. Stability constants during modeling were based on the 
MINTEQ.v4 database developed by the U.S. Environmental Protection Agency while 
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additional constants for complexation with solutions were modeled in equilibrium with 
CO2(g) (10
−4.8 atm.) and O2(g) (10
−0.67 atm.).39 The pH values predicted by PHREEQCi 
models were found to match the pH observed in experimental solutions. 
2.3.7 Fast Scan Controlled-Adsorption Voltammetry (FSCAV) 
A CFM was placed into a constantly stirred Cu(NO3)2 solution and a waveform (-
1.0 V – +1.3 V, resting potential of 0 V, at 600 Vs-1) was applied. An electronic relay 
(ADG-419, Analog Devices) was used to switch between the applied waveform and a 
constant potential of 0 V for 10 seconds to allow copper adsorption at the electrode 
surface reach equilibrium. After 10 seconds, the waveform was reapplied, and the first 
background-subtracted cyclic voltammogram was collected and analyzed for total 
adsorbed copper. In house LabVIEW 2012 software integrated the reduction peak from 
the background subtracted cyclic voltammogram of Cu2+ and Faraday’s law was used to 
convert this to a surface concentration (ΓCu). Measured data was fit to the linearized 
Langmuir isotherm (eq. 1) where C is the [Cu2+] in bulk solution, Γmax is the maximum 
monolayer surface coverage, and K is the equilibrium constant for adsorption. This 







           (1) 
2.3.8 Atomic Force Microscopy (AFM) 
CFMs were prepared as described above and electrochemically activated. During 
slow scan cyclic voltammograms of Cu(NO3)2 (100 µM) (from +1 V to -1 V , back to +1 
V), electrodes were temporarily disconnected for groups of electrodes at 6 different 
points. Those were 0.2, -0.6 and -1 V on the forward scan and -0.6, -0.3 and 0.2 V on the 
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reverse scan, all vs. Ag/AgCl. These electrodes had been exposed only to a partial section 
of the waveform. Electrodes were stored in a closed container and transported to the 
AFM. AFM images were taken using a Park Systems XE-NSOM instrument with a non-
contact tip. 
2.4 Results and Discussion 
2.4.1 Slow Scan Cu2+ Cyclic Voltammetry at CFMs 
During slow-scan Cu2+ cyclic voltammetry, a cathodic potential sweep is applied 
to the electrode at 1 – 10 mVs-1, followed by an anodic sweep that brings the potential 
back to rest36. During the cathodic scan, copper is deposited on the electrode surface 
following a nucleation and growth mechanism. Copper nucleates over a broad potential 
range. These nuclei allow more Cu to deposit during a growth phase at any potential 
sufficient for deposition. Therefore, there are often two broad ‘loop’ reduction peaks, 
between the same voltages, on both cathodic and anodic scans36. The differences between 
the nature of the electrode surface and the Cu surface make this nucleation/growth 
deposition occur at a more negative voltage than the standard Cu2+ reduction 
potential40,41. Indeed when holding a CFM at a constant potential of 0.34 V (Cu2+ 2e-→ 
Cu(s) standard reduction potential), addition of Cu(NO3)2 induced no change in current. 
This behavior is true for holding potentials down to -0.1 V (data not shown). During the 
anodic scan, the deposited Cu(s) is stripped off the electrode surface. Because this happens 
from a Cu(s) rich surface (a single phase), the stripping or oxidation peak is sharp and its 
voltage is much closer to the standard equilibrium potential40,41. Metal deposition can 
also occur via other mechanisms, for example, adsorption, charge transfer, and under 
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potential deposition (UPD)42-44. UPD is a process by which a metal deposits onto another 
metal at a more positive electrode potential than the Nernst potential for bulk 
deposition42. 
Figure 2.1. Slow scan cyclic voltammograms of Cu(NO3)2 on (a) AuM and (b) CFM at a 
scan rate of 10 mVs-1 in NaCl. Peaks A’ – E’ appear on the AuM, whereas peaks A – D 
appear on the CFM. 
 
CFM slow scan cyclic voltammetry of Cu2+ was probed here by comparisons to 
AuMs. Figure 2.1 shows representative cyclic voltammograms of Cu(NO3)2 (100 µM) on 
a Au Microelectrode (AuM) (a) and a CFM (b) at 10 mVs-1 in NaCl. These two 
voltammograms share common features. For example, Cu2+ reduction to metallic Cu 
begins at -0.1 V (peaks A’, A) and continues via a loop formation between -0.4 V and -
1.0 V on the cathodic scans (peaks B’, B). This loop formation is an indication of 
nucleation and growth processes and is similar to previous observations.43 On both AuMs 
and CFMs, sharp stripping peaks (C’, C) and shoulder peaks (D’, D) are present between 
-0.1 to 0.2 V on the anodic scans.  Shoulders accompanying stripping peaks have 
previously been reported on glassy carbon electrodes44 and highly oriented pyrolytic 
graphite electrodes43. The presence of complexing agents such as chloride and ammonia 
strongly affect copper redox processes and lead to the observation of shoulder peaks at 
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potentials higher than stripping peaks41,43-47. Shoulder peaks have not been found to be 
associated with stripping peaks in media containing no complexing agents40,48-51.  
A mechanism for shoulder peak formation in the presence of Cl- has been 
speculated previously44,47,52. First, deposited Cu oxidizes to Cu+, creating a stripping peak 
(C’, C) and forming a barely conductive, passive layer of CuCl according to reaction (2).  
Cu + Cl- → CuCl + e- -----------------(2) 
The CuCl layer shields underlying metallic copper thereby momentarily arresting 
further oxidation. Dissolution of this passive layer occurs either via direct diffusion or 
diffusion of a more soluble complex (such as CuCl2
-). Dissolution exposes the remaining 
underlying metal allowing the electro-oxidation of Cu to continue as shown in reactions 
(3) and (4):  
CuCl + Cl- → CuCl2
-  ---------------------------(3) 
CuCl2
-→ Cu2 + + 2Cl- + e- ----------------------(4) 
We determined whether these processes are responsible for shoulder peaks D’ and 
D by systematically increasing the scan rate as described in the next section. There is an 
additional peak on the AuM that is not present on the CFM (peak E’). UPD plays a 
significant role in copper deposition on gold surfaces42 whereas on carbon materials, 
metallic copper follows bulk deposition with no evidence for UPD41,43,44,46,48,53. Peak E’ 
on the AuM is likely a consequence of anodic processes associated with UPD on gold42.  
2.4.2 Scan Rate Dependence  
The shoulder peak mechanism proposed above was tested on CFMs by 
progressively increasing scan rate. The rationale here is that by increasing scan rate, 
nucleation/growth and hence stripping become limited because these processes are mass-
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transport dependent.41 Because reactions (3) and (4) rely on the stripping peak, any 
limitations in stripping should manifest proportionally on the shoulder peak. 
In this experiment cyclic voltammograms of Cu(NO3)2 were collected at CFMs at 
increasing scan rates. From 10 – 100 mVs-1, raw traces were analyzed; however at higher 
scan rates, the charging current due to double layer capacitance dominates the Faradaic 
component of the voltammetric signal. Therefore, cyclic voltammograms at 1 Vs-1 and 
above were collected in a flow injection system (FIA) using background subtraction.  
Figure 2.2 shows cyclic voltammograms collected at 10, 30, 50 and 100 mVs-1 
(left, blue panel) and at 1, 50, 100 and 300 Vs-1 (right, green panel). This experiment 
illustrates the evolution of a slow scan Cu(NO3)2 cyclic voltammogram in a typical FSCV 
signal33. Increased peak separation at high FSCV scan rates is due to slow electron 
transfer kinetics. All peaks are labeled as in Figure 2.1. From 10 – 100 mVs-1, the 
magnitude of peaks (B) and (C) are greatly reduced such that they are almost absent at 
100 mVs-1. This is consistent with the notion that nucleation and growth are mass-
transport limited and therefore can be ‘outrun’ at high scan rates. The magnitude of peaks 
(A) and (D) however are not subject to the same behavior. Peaks (A) and (D) are present 
and well defined at 100 mVs-1 implying that these features are neither mass-transport 
limited nor dependent on peaks (B) and (C). The results of these experiments indicate 





Figure 2.2. Left: Slow scan cyclic voltammograms of Cu(NO3)2 on CFMs at scan rates of 
10, 30, 50 and 100 mVs-1. Right: Fast scan background-subtracted cyclic voltammograms 
of Cu(NO3)2 at scan rates of 1, 50, 100 and 300 Vs
-1.  
 
For adsorbed species, the peak current is proportional to scan rate51 and we indeed 
found that from 1 – 300 Vs-1, peak amplitudes increased. Furthermore, the slope of a plot 
of the log current vs. log scan rate for Cu(NO3)2 was previously reported to be 
approximately 1 at high scan rates33. Taken together, these findings strongly support a 
hypothesis that peaks (A) and (D) stem from an adsorption controlled process. 
Adsorption is explored in the following sections. 
2.4.3 CFM Over-oxidation Leads to Enhanced Sensitivity 
Activated carbon is widely used in wastewater treatment and is the primary 
purification component of domestic water filters54,55. When carbon is activated (e.g. via 
heat in the presence of air, or with chemical or electrochemical pretreatments) a wide 
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array of oxygen functionalities are created on its surface54. These oxygen moieties adsorb 
and complex trace metals, removing them from solution56,57.  
CFMs are typically electrochemically pre-treated prior to use56. Therefore, in 
analogy to metal adsorption by activated carbon, the oxygen functionalities on the CFM 
surface may rapidly complex trace metals in solution, pre-concentrating them on the 
surface. In this experiment, we tested the hypothesis that enhanced surface oxidation is 
responsible for increased FSCV sensitivity towards Cu2+, presumably due to an increased 
number of adsorption sites.  
Figure 2.3. Maximum cathodic current of Cu(NO3)2 (10 µM) fast scan cyclic 
voltammograms as a function of anodic potential limit (blue series) at 300 Vs-1 and as a 
function of acid pretreatment (green).  
 
Using flow injection analysis, we collected background subtracted cyclic 
voltammograms of CFMs exposed to a bolus of Cu(NO3)2 (10 µM) with different FSCV 
waveforms. We systematically increased the anodic potential limit of the waveform at a 




Figure 2.4. (a) Langmuir adsorption isotherms for Cu(NO3)2 on CFMs in NaCl (top) and 
in tris buffer (bottom). (b) Histogram showing % [Cu2+]free in solution and % cathodic 
current of Cu(NO3)2 (10 µM) in NaCl (purple series) and in tris buffer (black series) at 
300 Vs-1 (% cathodic current is shown by setting the maximum cathodic current with tris 
buffer to 100% and expressing the cathodic current with NaCl as a percentage of this). 
The inset background-subtracted cyclic voltammograms are representative examples 
taken in NaCl (purple) and tris buffer (black) 
 
Figure 2.3 shows the magnitude of cathodic current (demonstrated by the inset 
cyclic voltammogram) as a function of the anodic potential limit. The cathodic current 
showed exponential increases with increasing anodic potential. This exact behavior was 
previously reported with neurotransmitters and attributed to surface ‘activation’ or over-
oxidation56. To confirm that the enhanced sensitivity was due to over-oxidation, an 
alternative method to over-oxidize the CFM surface was employed. An acid pretreatment 
38 was applied to the electrode surface prior to use (H2SO4 (0.25 M) and HNO3 (0.25 M) 
in a 3:1 ratio).  An anodic potential limit of +0.6 V was used where we previously found 
negligible effects of electrochemical over-oxidation. The resultant cathodic current is 
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plotted in green on the 0.6 V series. The current here is substantially higher than the non-
acid treated CFM confirming that surface activation, by two separate means, begets 
similar outcomes. 
2.4.4 Cu2+ Adsorption to CFMs drives the FSCV Signal 
We sought to verify that the enhanced FSCV sensitivity towards Cu2+ as a 
consequence of activation is an adsorption-driven mechanism. This was successfully 
confirmed by construction of adsorption isotherms using fast scan controlled-adsorption 
voltammetry (FSCAV) on CFMs57. Adsorption isotherms describe the thermodynamic 
equilibrium of Cu2+ onto the CFM, providing an index of the amount of Cu2+ on the CFM 
surface with respect to bulk solution via the equilibrium constant, K.  
In all experiments described above, we used a simple matrix, NaCl, for 
characterizations. The adsorption isotherm of Cu2+ on CFMs in NaCl is shown in Figure 
2.4a (top panel) and follows a Langmuir fit.  Authentic biological and environmental 
matrices are more complicated than NaCl and contain copper binding components. 
Therefore, we studied whether a complex matrix would affect Cu2+ adsorption. We 
previously characterized copper in tris buffer33 which has considerable metal binding 
capacity58,59. Additionally Tris acts as a model biological medium because it contains 
amines that mimic proteins. The other salts in the buffer are at a ratio and concentration 
designed to mimic artificial cerebrospinal fluid (ACSF). Many neurotransmitters and 
other biologically relevant molecules have been characterized in tris in vitro60-62 therefore 
adsorption isotherms were additionally constructed in tris buffer, (Figure 2.4a bottom) 
also following a Langmuir fit.  
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We previously used a geochemical model to calculate the equilibrium 
concentrations of free Pb2+ in test solutions32. We employed the same model here to 
calculate free Cu2+ concentration ([Cu2+]free) in NaCl and tris solutions.  Our isotherms 
therefore have two x-axes, (A) denotes the concentration of Cu2+ added ([Cu2+](N)) to the 
test solutions and (B) denotes the free Cu2+ concentration [Cu2+]free in solution. For NaCl, 
the two x-axes values are similar because NaCl has little Cu2+ binding capacity. Therefore 
when calculating K, there is little difference between the values calculated with [Cu2+](N) 
vs. [Cu2+]free (KA and KB).  For tris the values of axes (A) and (B) are dramatically 
different because tris has Cu2+ binding capacity with K  104 59. It is interesting however, 
that when [Cu2+]free is taken into consideration in the calculation, K (KB) is similar to the 
K values in NaCl. Therefore, this complex matrix does not affect the monolayer 
characteristics of Cu2+ adsorption onto CFMs. This experiment further shows that 
solution complexes and other species do not significantly adsorb to the CFM surface and 
alter K. 
The interactions of the Cu2+- CFM and Cu2+ - tris equilibria are complicated.  
Figure 2.4b is a histogram that compares % [Cu2+]free in solution to the cathodic current 
of background subtracted cyclic voltammograms of Cu(NO3)2 in NaCl (purple series) and 
tris buffer (black series). Shown in the inset are representative examples of cyclic 
voltammograms of Cu(NO3)2 in NaCl and tris buffer. In the histogram, we compared the 
two FSCV signals thus: the maximum cathodic current with tris buffer was normalized to 
100% and the current with NaCl was expressed as a percentage of this. It is seen that 
despite only 2% [Cu2+]free in tris buffer, that the Cu
2+ signal is 9.2% of the Cu2+ signal in 
NaCl (with 98% [Cu2+]free). This discrepancy implies that the two equilibria compete. The 
 
34 
equilibrium of Cu2+- CFM complexation is more favorable than Cu2+ - tris complexation, 
and a serendipitous outcome of this effect is high FSCV sensitivity, even in Cu2+ 
complexing matrices. 
Given the confirmation that our Cu2+ FSCV signal is highly adsorption driven, the 
nucleation characteristics of the cyclic voltammetry peaks on CFMs were next studied. 
 
Figure 2.5. AFM images of a slow scan (10 mVs-1) cyclic voltammogram of Cu(NO3)2 
(100 µM) in tris buffer taken at six different points along the scan. On the forward scan, 
images were recorded at 0.2 V (i), -0.6 V (ii) and -1 V (iii) and on the backward scan at 








2.4.5 AFM Characterization of Cu Nucleation and Oxidation 
Changes in the morphology of the CFM surface can be visualized with AFM.  
AFM is a sensitive surface imaging technique, which employs a cantilevered tip to 
convert surface contours into images.  AFM is routinely used to establish and 
characterize the formation of metallic copper on electrode surfaces40,41. In Figure 2.5, 
AFM images were recorded at six different points along a slow scan cyclic 
voltammogram of Cu(NO3)2 in a complex matrix, tris buffer. Shortly after the start of the 
scan (i) the striations of the bare CFM surface are well defined. The small round features 
on the surface are likely solid contaminants.  At (ii), metallic copper clusters are present 
on the CFM surface showing that the eventual cathodic FSCV peak (which evolves from 
this peak at high scan rates) involves deposition of Cu(s).  Cu(s) is more elaborate during 
nucleation (iii) and after growth (iv) where striations are no longer visible under metallic 
Cu.  After stripping (v), striations are again visible and due to the removal of metallic Cu.  
During the stripping process, Cu(s) may either be oxidized to Cu
+ (as discussed above) or 
directly to Cu2+. The presence of clear carbon striations and the scan rate dependent data 
provide little evidence for the formation of CuCl.  However, the nature of the peak 
directly proceeding the stripping peak (the eventual anodic FSCV anodic peak) is yet to 
be determined.  One explanation is that this Cu(s) is deposited on specific CFM adsorption 
sites that have their own discrete oxidation potentials.  The remaining clusters are no 




These surface morphology data confirm the nucleation and oxidation of metallic 
Cu associated with the cathodic and anodic FSCV peaks, i.e., peaks A and B in the FSCV 
segment of Figure 2.2 are due to Cu2+ + 2 e- → Cu(s) and the reverse reaction.  
2.5 Conclusion 
FSCV at CFMs is an excellent tool for fast metal analysis with essential 
applications in biology and the environment. In this work, we described the fundamental 
mechanisms of fast scan voltammetry of Cu2+ on CFMs. In analogy to metal remediation 
by activated carbon, we showed that adsorption on CFMs underlies rapid FSCV 
responses. We ascertained the thermodynamic and physical characteristics of the CFM 
adsorption mechanism.  This study has allowed us to understand the fundamentals of 
Cu2+ FSCV, enabling future improvements in the sensitivity and selectivity of fast metal 
voltammetry for real-time biological and environmental analysis. 
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Histamine plays a major role in the mediation of allergic reactions such as 
peripheral inflammation. This classical monoamine is also a neurotransmitter involved in 
the central nervous system but its roles in this context are poorly understood. Studying 
histamine neurotransmission is important due to its implications in many neurological 
disorders. The sensitivity, selectivity and high temporal resolution of fast scan cyclic 
voltammetry (FSCV) offer many advantages for studying electroactive neurotransmitters. 
Histamine has previously been studied with FSCV; however, the lack of a robust 
Faradaic electrochemical signal makes it difficult to selectively identify histamine in 
complex media, as found in vivo.  In this work, we optimize an electrochemical 
waveform that provides a stimulation-locked and unique electrochemical signal towards 
histamine. We describe in vitro waveform optimization and a novel in vivo physiological 
model for stimulating histamine release in the mouse premamillary nucleus via 
stimulation of the medial forebrain bundle. We demonstrate that a robust signal can be 
used to effectively identify histamine and characterize its' in vivo kinetics. 
3.2 Introduction 
The central nervous system holds four aminergic systems, dopamine, serotonin, 
norepinephrine and histamine. These messengers are in an intricate chemical interplay 
with one-another and other neurotransmitters to precisely modulate many aspects of brain 
function. It is critical to understand the fundamental neurochemistry of these four 
modulatory systems to better prevent, diagnose and treat brain disorders and diseases. 




uniquely powerful method for in vivo analysis. CFMs are biocompatible, cause negligible 
damage to brain tissue and, because of their kinetically favorable surface kinetics, 
provide real-time output of electroactive neurotransmitters.  
The dopaminergic system has been extensively studied with FSCV over the 
previous three decades leading to breakthroughs in understanding dopaminergic 
mechanisms in the brain1-3. More recently, FSCV has been recently developed for the 
detection of serotonin and norepinephrine4,5 and many important aspects of the two 
neurotransmitters are thus being unearthed6-10. Histamine is also an electroactive amine, 
and there have been previous reports of histamine induced FSCV signals in mast cells,11-
13 brain tissue slice preparations14 and in vivo15, however mechanistic studies on 
histamine are limited. This is primarily because histamine electrochemistry is complex, 
and FSCV induced histamine signals are often interpreted via changes in the capacitative 
current on the electrode surface. This approach is fully quantitative, however many 
analytes induce a capacitative change at the electrode surface limiting selectivity and 
rendering in vivo studies very difficult.  
Faradaic electrochemistry more selectively identifies analytes because of the 
unique potential position of redox peaks16. In this paper, we discuss the relevance of 
histamine adsorption to capacitative currents at CFMs. We describe a novel FSCV 
waveform that generates a robust oxidation peak in response to histamine. We show in 
vitro, that histamine can be detected selectively and with high sensitivity. Finally, we 
report and verify a robust histamine signature in the mouse premamillary nucleus (PM) in 




Our novel FSCV waveform for histamine provides a tool that will enable the same 
level of investigation for histamine as other, more established brain amines. Histamine’s 
roles in the brain, in particular with respect to disorders in which it is implicated (e.g. 
Alzheimer’s disease) can thus be systematically studied. 
3.3 Experimental Section 
3.3.1 Chemicals and Reagents 
Standard solutions were prepared by dissolving histamine dihydrochloride, 
dopamine hydrochloride, serotonin hydrochloride and adenosine hydrocloride (Sigma-
Aldrich, Co., MO, USA) respectively in Tris-buffer. Tris-buffer was constituted thus: 15 
mM H2NC(CH2)(OH)3.HCl, 140 mM NaCl, 3.25 mM KCl, 1.2 mM CaCl2, 1.25 mM 
NaH2PO4.H2O, 1.2 mM MgCl2 and 2.0 mM Na2SO4 at pH=7.4 in deinoized water (EMD 
Chemicals Inc. NJ, USA). 
3.3.2 Carbon-Fiber Microelectrodes (CFMs) 
CFMs were fabricated with 7µm diameter carbon-fibers (Goodfellow 
Corporation, PA, USA) aspirated in to glass capillaries (0.6 mm external diameter, 0.4 
mm internal diameter, A-M systems, Inc., Sequim, WA). A carbon-glass seal was formed 
via a vertical micropipette puller (Narishige Group, Tokyo, Japan). The exposed length of 
the carbon fiber was trimmed to 150 µm under an optical microscope. Microelectrodes 






3.3.3 Data Collection/Analysis 
Waveform generation was via a PCIe-6341 DAC/ADC card (National 
Instruments, Austin, TX). Output current was measured by a CHEM-CLAMP 
potentiostat (Dagan corporation, MN). Custom built software was employed to drive the 
hardware, collect data and perform analysis including background subtraction, signal 
averaging and digital filtering (Knowmad Technologies LLC, Tucson, AZ). All potentials 
are quoted with respect to Ag/AgCl reference electrodes, which were fabricated via 
electrodeposition of Cl- by holding a silver wire (A-M systems, WA) at 4.0 V for 5 s in 1 
M HCl. All data represented with error bars represent the standard error of the mean 
(SEM). Statistical differences were determined using one-tailed student’s-tests on paired 
data sets (p<0.45 was taken as statistically different). 
3.3.4 Langmuir Adsorption Isotherms 
A CFM was placed into histamine solution of standard concentration and an 
optimized histamine waveform was applied. An electronic relay (ADG-419, Analog 
Devices) was used to switch between the applied waveform and a constant potential (-0.5 
V) for 10 seconds to allow histamine adsorption at the electrode surface and reach 
equilibrium. After 10 seconds, the waveform was reapplied, and the first background-
subtracted cyclic voltammogram was collected and analyzed for total adsorbed histamine. 
In house LabVIEW 2012 software integrated the oxidation peak from the background 
subtracted cyclic voltammogram and Faraday's law was used to convert this to a surface 




isotherm as previously described17, and K is the equilibrium constant for adsorption. This 
experiment was performed in tris buffer (15 mM). 
3.3.5 Flow Injection Analysis 
In vitro analyses were performed with flow injection analysis (FIA). CFMs were 
inserted into a flangeless short 1/8 nut (PEEK P-335, IDEX, Middleboro, MA) such that 
around 2 mm of the tip remained exposed outside of the nut. The microelectrode-
containing nut was then fastened into a modified HPLC union (Elbow PEEK 3432, 
IDEX, Middleboro, MA). The other end of the elbow union was fastened into the out-
flowing steam of the FIA buffer and two holes were drilled into the union for 
incorporation of the reference electrode and for a ‘waste’ flow stream. Flow was 
maintained with a syringe infusion pump (kd Scientific, model KDS-410, Holliston, MA) 
at 2 mL min-1. A rectangular pulse of analyte was introduced into the flow steam for 10 s 
via a six-port HPLC loop injector (Rheodyne model 7010 valve, VICI, Houston, TX). For 
calibrations and waveform optimization, analytes were injected in random concentrations 
order to avoid carry-over effects. 
3.3.6 Potentiometry 
The open circuit potential between CFMs and Ag/AgCl was measured using a 
potentiostat with an integrated high impedance amplifier (eDAQ Pty Ltd, NSW, 
Australia). 200 µM of histamine was injected onto the CFM in Tris-buffer using FIA at 





3.3.7 Animal Surgeries 
Handling and surgery on male C57BL/6J mice weighing 20−25 g (Jackson 
Laboratory, Bar Harbor, ME) were in agreement with The Guide for the Care and Use of 
Laboratory Animals, approved by the Institutional Animal Care and Use. Urethane (25% 
dissolved in 0.9% NaCl solution, Hospira, Lake Forest, IL) was administered via 
intraperitoneal (i.p.) injection, and stereotaxic surgery (David Kopf Instruments, Tujunga, 
CA) was performed. A heating pad sustained mouse body temperature around 37 °C 
(Braintree Scientific, Braintree, MA). Stereotaxic coordinates were taken in reference to 
bregma. A Nafion modified CFM was inserted into the PM (AP: −2.45, ML: +0.50, DV: 
−5.45 to −5.55.). A stainless steel stimulating electrode (diameter: 0.2 mm, Plastics One, 
Roanoke, VA) was positioned into the MFB (AP: -1.07, ML: +1.10, DV: −5.00). 120 
biphasic pulses were applied through a linear constant current stimulus isolator (NL800A, 
Neurolog, Medical Systems Corp., Great Neck, NY). The 60 Hz trains were 350 μA each 
phase, 2 ms in width, and 2 s in length. An Ag/AgCl reference electrode was implanted 
into the brain’s opposite hemisphere. 
3.3.8 Drugs 
Tacrine hydrochloride (2 mg kg-1) and thioperamide maleate (20 mg kg-1) from 
TOCRIS bioscience (Bristol, UK) were dissolved in saline respectively and injected i.p. 






3.4 Results and Discussion                                                                                                                  
3.4.1 Histamine Adsorption onto CFMs Underlies Capacitative FSCV Current 
Histamine has previously been detected in mast cells and neural tissues with 
FSCV11-15. In the majority of these studies, the oxidation peak that appeared at or after 
the switching potential on the positive wave, as illustrated in Figure 3.1, was used for 
quantification. Figure 3.1Ai is an FSCV color plot during flow injection of histamine (20 
µM) onto a CFM with a serotonin sensitive waveform18. The interpretation of color plots 
is described in detail elsewhere19, briefly, potential is displayed on the y-axis, time on the 
x-axis and current in false color and injection time is denoted by the star. 
Figure 3.1. A shows color plots for FIA of (i) 20 µM histamine (ii) 10 µM adenosine. B 
shows CVs extracted from the vertical dashed lines from (i) and (ii). 
A cyclic voltammogram (CV) taken from the vertical white dashed line of the 
color plot displays an oxidation peak at around 0.8 V that appears after the switching 
potential (on the returning positive scan). In previous work, a stimulation-locked signal in 
the rat substantia nigra (SNr) displayed a similar CV and was pharmacologically 
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to selectively verify histamine with this waveform, this is because other electroactive 
species give identical CVs. Figure 3.1Aii is a color plot taken during FIA of adenosine 
(10 µM). The corresponding CV (Figure 3.1B) is almost identical to that of histamine’s. 
In a region containing both adenosine and histamine, therefore, it is not possible to 
distinguish between these analytes electrochemically. Furthermore, other work has shown 
similar CVs for H2O2 and gonatropin-releasing hormone
20,21, further complicating 
selective histamine detection. 
Histamine electrochemistry is kinetically limited within the oxidation potential 
window of previously utilized waveforms. In fact the electrochemical oxidation scheme 
for histamine is not known, presumably because it involves charge transfer. We therefore 
postulate that the peaks observed in Figure 3.1 are due to non-Faradaic processes. These 
processes arise on the CFM surface when spontaneous adsorption of histamine causes 
changes in the electrical bilayer. The electrical bilayer on electrode surfaces acts as a 
capacitor, discharging current into the electrode, particularly at switching potentials. 
Capacitative or charging currents are a well-known phenomenon in FSCV because of the 
high scan rates employed16. FSCV is background-subtracted, specifically to remove such 
background charging currents which do not reflect Faradaic processes associated with 
analytes of interest. However, adsorption of histamine changes the background 
capacitative current which cannot be subtracted out, this effect manifests as the features 
in the CVs in Figure 3.1.  
In Figure 3.2, FIA was utilized to inject histamine (200 µM) onto CFMs while 
the open field potential was measured vs. Ag/AgCl (Figure 3.2A). Figure 3.2B shows 




there is no driving potential, this implies that histamine spontaneously adsorbs to and 
changes the potential of the CFM. The features on histamine’s CV in Figure 3.1 are 
likely a consequence of the current that arises from this adsorption. To further verify this 
histamine adsorption, Langmuir isotherms were constructed for histamine with a 
previously described method22 confirming monolayer coverage of the CFM (Figure 
3.2C). 
While charging current peaks can quantify histamine, little selectivity is offered 
since many analytes adsorb onto CFMs. We therefore designed a novel waveform to 
capture histamine electrochemistry before the switching potential. 
 
Figure 3.2. A shows the schematic diagram of the experimental setup used for 
potentiometric experiments. B shows the experimental potentiometric data for five 
consecutive injections of histamine (200 µM) on CFM. C Langmuir isotherm for 
histamine adsorption on CFMs in Tris buffer. 
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3.4.2 Histamine Selective Waveform (HSW) 
Histamine contains an imidazole ring and an aliphatic amine group. This 
molecule’s ability to readily bind metals such as Cu23,24, because of its electronegative 
sites, means that it is readily amenable to oxidation. However histamine electro-oxidation 
differs from serotonin and dopamine in that it likely involves charge transfer. This 
mechanism introduces kinetic limitations that have not yet enabled stimulation-locked 
peaks on the positive direction of the wave in FSCV studies. Therefore preliminary we 
utilized a triangular waveform and expanded the potential window to cover a large range 
thereby allowing histamine oxidation to occur within a single scan. Through trial and 
error we determined that, in vitro, a waveform scanning from -0.7 to 1.1 V (resting at -0.7 
V at 600 Vs-1) provided an oxidation peak during the positive scan. However this 
waveform was not successful in vivo, showing rapid degradation (fouling). By changing 
the resting potential to -0.5 V, we found that electrode degradation was eliminated and in 
vivo detection was possible. A possible explanation for this phenomenon is that at -0.7 V, 
fouling species (e.g proteins) may preferentially adsorb onto the electrode surface.  
Our optimized waveform, the histamine selective waveform (HSW), therefore is -
0.7 V to 1.1 V, resting at -0.5 V, with a scan rate of 600 Vs-1. Figure 3.3 compares 
histamine detection with the previously described serotonin waveform15 to the HSW. 
Figure 3.3A (serotonin waveform) and C (HSW) show color plots and CVs during FIA 
of histamine (20 µM). The HSW detects histamine oxidation at around     +0.3 V vs. 
Ag/AgCl, and in contrast to the serotonin waveform, this peak occurs before the 
switching potential on the positive wave.  Furthermore, current vs. time traces, extracted 




response is a square injection while the serotonin waveform response does not reach 
steady state. This makes it possible to more accurately describe histamine in vivo kinetics 
(i.e. histamine clearance kinetics) with the HSW. The HSW has a linear dynamic range 
up to 20 µM of histamine (Figure 3.3Dii), a sensitivity of 0.354 ± 0.032 nA/µM and a 
limit of detection of 1 µM. Finally, histamine measurements with this waveform show 
good stability, as evidenced by the negligible loss in signal (normalized oxidation 
current) during 50 successive flow injections of histamine (10 µM) (Figure 3.3E). 
3.4.3 HSW Selectivity  
We sought to develop a waveform to produce a histamine oxidation peak before 
the switching potential on the positive scan to increase the selectivity of FSCV towards 
histamine. To assess the selectivity of the waveform in vitro, we tested dopamine, 
serotonin and adenosine, which are electroactive species that are chemically similar to 
histamine and commonly found in brain regions containing histamine25,26,27. Figure 3.4 
shows CVs obtained during FIA of histamine (20 µM), dopamine (100 nM), serotonin 
(10 nM) and adenosine (1 µM). These concentrations were chosen to mimic previously 
reported evoked in vivo concentrations11,26,28. Adenosine’s peak still occurs at the 
switching potential with this waveform and is therefore unlikely to interfere. The 
oxidation peak for histamine appears at around 0.3 V vs. Ag/AgCl (green dashed line) 
and is in a different position from dopamine and serotonin oxidation peaks (around 0.5 





         
Figure 3.3. A & C show color plots for FIA of 20 µM histamine with the serotonin and 
HSW waveforms respectively. CVs extracted from vertical dashed lines are shown on the 
right. B shows Current vs. time traces from the horizontal dashed lines from color plots. 
D shows (i) Calibration curve, (ii) Linear dynamic range (n=4 ± SEM). E Stability of 
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Figure 3.4. CVs for 20 µM histamine, 100 nM dopamine, 10 nM serotonin and 1 µM 
adenosine with in vitro FIA using HSW on CFMs. Vertical dashed lines indicate potential 
positions of peaks. 
The HSW therefore shows good selectivity in vitro. However, the in vivo matrix 
is far more complicated than can be reproduced on the bench. We next assessed the 
ability of our novel waveform to measure histamine in vivo.  
In Vivo Histamine 
Histamine and serotonin were previously found to be co-released in the SNr upon 
electrical stimulation of the MFB15. We were interested in isolating a histamine signal in 
a novel physiological circuitry involving the histamine cell bodies. Histamine cell bodies 
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their afferents to the forebrain via the MFB29,30,31. By utilizing a retrograde-stimulation15 
of the MFB, we reasoned that we would be able to detect histamine in the PM since 



















Figure 3.5. A shows a representative colors plot of in the PM upon MFB stimulation. B 
shows a representative in vitro color plot of histamine (20 µM) using FIA.  C shows 
[histamine] vs. time extracted from the horizontal dashed line from color plot A. D shows 
normalized CVs of in vivo and in vitro (5 µM histamine) signals taken from vertical 
dashed lines. 
 
Figure 3.5A shows a color plot in the mouse PM upon MFB stimulation (at 5-7 
seconds indicated with the blue bar). An event at around 0.3 V vs. Ag/AgCl is clearly 
visible: a vertical dashed line through the maximum amplitude of this event (at 7 s) 
provides the CV in Figure 3.5D. When a CV collected for histamine in vitro (Figure 
3.5B) was normalized and superimposed onto this in vivo CV, there was very good 
agreement between the oxidation peaks at 0.3 V. The additional features of the in vivo 
CV are due to the capacitative changes on the electrodes surface because of changes in 
the in vivo environment (ionic fluxes, pH changes). Where it not for the peak at 0.3V, it 
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would be impossible to disentangle histamine’s electrochemistry from this other 
electrochemisty occurring at the switching potential. 
Figure 3.5C shows how histamine changes with time, determined by extracting 
current vs. time from the horizontal dashed line of the color plot and the calibration curve 
in Figure 3.3D. Histamine levels elevate in response to electrical stimulation to around 8 
µM and then clear after the stimulation, similar in magnitude to histamine release from 
mast cells11. This profile is similar to dopamine and serotonin reuptake10,33. This is an 
important finding since it implies a similar reuptake system for histamine, however a 
histamine transporter is yet to be identified34. 
Although the electrochemistry is supportive of histamine’s identity. It is necessary 
to perform pharmacological experiments to validate the histamine response. Histamine 
neuropharmacology is not well explored in voltammetry models and there are very few 
histamine selective compounds that can cross the blood brain barrier. As a first step, we 
utilized tacrine, a pharmaceutical therapy for Alzheimer’s disease. Tacrine is thought to 
primarily inhibit acetylcholinesterase, however it also is a potent inhibitor of histamine 
N-methyltransferase (HNMT) (histamine metabolizing enzyme)35-37. Figure 3.6 shows 
the effect on the evoked PM signal (schematic of circuitry shown in Figure 3.6A) upon 
i.p. tacrine (2 mg kg-1)38 administration (n=5 animals ± SEM). Consistent with tactrine’s 
pharmacokinetic profile in rodents39, there was a clear effect 50 minutes after 
administration, whereby the t1/2 of histamine clearance increased significantly from 10.9 ± 
1.1 s to 15.44 ± 2.6 s (p=0.01) (Figure 3.6B). This is an expected result of inhibition of 




enzyme raises cystolic histamine levels which slows down the reuptake equilibria back 
into the cell. 
 
 
Figure 3.6. A shows the positions of electrodes (stimulation and CFM) in mouse brain. B 
& D show representative color plots of stimulated release of histamine using HSW - 
before and after tacrine (2 mg Kg-1) and thioperamide (20 mg Kg-1). C & E show 
concentration vs. time traces extracted from horizontal dashed line from B & D 
respectively, (n=5 ± SEM). The 2 s stimulation starting at 5 s is shown by the blue bar. 
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Because tacrine is non-selective, we performed a further pharmacological 
experiment to verify the PM signal. Thioperamide is a selective H3 receptor antagonist. 
We would expect thioperamide administration to affect the kinetics of histamine release 
and clearance via inhibition of these histamine autoreceptors in the PM42. Figure 3.6C 
and D show that 50 minutes after thioperamide (20 mg kg-1)43, there was a pronounced 
increase in histamine release from  7.9 ± 2.1 to  11.8 ± 4.6 μM (p=0.02). Increases in 
evoked release have previously been seen with dopamine and autoreceptor 
antagonism44,45. A significant increase in the t1/2 of histamine clearance was also observed 
from 13.3 ± 3.4 s to 18.8 ± 3.2 s (p=0.03), which was seen in prior studies with serotonin 
autoreceptor antagonism10. The time course of this experiment is also consistent with 
thioperamide’s pharmacokinetics in rodents46. These pharmacological experiments, in 
addition to the electrochemical characterization allow us to confidently verify the 
histamine nature of this signal in the PM.  
3.5 Conclusion 
Histamine has important, but not well studied roles as a neurotransmitter. 
FSCV is an ideal tool for histamine detection because of its sensitivity, selectivity 
and high temporal resolution. Previous FSCV studies have not been able to 
selectively identify histamine because the CV features were due to capacitative 
processes on the electrode surface that are not selective.  Here, we developed the 
HSW that provides a robust oxidation peak before the switching peak. We described 
in vitro waveform optimization and a novel in vivo physiological model for 




pharmacologically as histamine. This novel FSCV method will enable detailed in 
vivo characterizations of this important neuromodulator. 
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Histamine and serotonin are neuromodulators which facilitate numerous, diverse 
neurological functions. Being co-localized in many brain regions, these two 
neurotransmitters are thought to modulate one another’s chemistry and are often 
implicated in the etiology of disease. Thus, it is desirable to interpret the in 
vivo chemistry underlying neurotransmission of these two molecules to better define their 
roles in health and disease. In this work, we describe a voltammetric approach to 
monitoring serotonin and histamine simultaneously in real time. Via electrical stimulation 
of the axonal bundles in the medial forebrain bundle, histamine was evoked in the mouse 
premammillary nucleus. We found that histamine release was accompanied by a rapid, 
potent inhibition of serotonin in a concentration dependent manner. We developed 
mathematical models to capture the experimental time courses of histamine and 
serotonin, which necessitated incorporation of an inhibitory receptor on serotonin 
neurons. We employed pharmacological experiments to verify that this serotonin 
inhibition was mediated by H3 receptors. Our novel approach provides fundamental 
mechanistic insights that can be used to examine the full extent of interconnectivity 
between histamine and serotonin in brain. 
4.2 Introduction 
Serotonin and histamine are neuromodulators thought to carry a variety of roles in 
the brain 1-3. These two modulators are co-localized in many brain regions 4,5 and are 
postulated to closely modulate one another 6,7. However, while there is much focus on 




to the same processes remains relatively neglected.  In recent years, we established fast 
scan cyclic voltammetry (FSCV) at carbon fiber microelectrodes (CFMs) to investigate in 
vivo serotonin dynamics 10. We are systematically studying the array of in vivo processes 
that regulate serotonin extracellular levels 11,12 with the ultimate goal of identifying 
distinct mechanistic abnormalities that underlie different pathophysiological states. 
Because of histamine’s close association with serotonin, in particular the 
electrophysiological, histological and slice voltammetry studies that imply histamine 
inhibits serotonin release 6,13-15 we now find it of great importance to direct our efforts to 
voltammetrically defining histamine and serotonin co-modulation in vivo. 
In this paper, we extend on recent work where we described the first 
voltammetrically selective waveform for real time FSCV histamine measurements in vivo 
in the mouse 16, to  detail simultaneous in vivo measurements of serotonin and histamine. 
To achieve this, CFMs were implanted in the mouse premammillary nucleus (PM), a 
hypothalamic region rich in serotonin and histamine 4,5,17. To assess the effects of 
histamine release on endogenous serotonin chemistry, we identified a discrete location in 
the medial forebrain bundle (MFB) that, when electrically stimulated, evoked histamine 
but not serotonin in the PM. This robust experimental model allowed us to observe 
histamine release rapidly followed by potent, long lasting serotonin inhibition. We found 
that both histamine release and serotonin inhibition were dependent on stimulation 
parameters in a manner that indicated an inversely correlative relationship. We 
mathematically modeled both responses and found that an inhibitory receptor term was 




receptor and provided pharmacological evidence, in the form of manipulations with 
thioperamide, an H3 receptor antagonist, in favor of our hypothesis.  
We thus provide not only an important technological advance, but our 
physiological findings also represent an opportunity to more closely scrutinize 
histamine’s roles in controlling serotonin chemistry in the context of disease. 
4.3 Materials and Methods 
4.3.1 Chemicals and Reagents 
Standard solutions were prepared by dissolving histamine dihydrochloride and 
serotonin hydrochloride (Sigma-Aldrich, Co., MO, USA) respectively in Tris-buffer. 
Tris-buffer was constituted thus: 15 mM H2NC(CH2OH)2.HCl, 140 mM NaCl, 3.25 mM 
KCl, 1.2 mM CaCl2, 1.25 mM NaH2PO4.H2O, 1.2 mM MgCl2 and 2.0 mM Na2SO4 
(EMD Chemicals Inc. NJ, USA) in deinoized water at pH=7.4 Thioperamide maleate (2, 
20, or 200 mg kg-1) from TOCRIS bioscience (Bristol, UK) was dissolved in sterile saline 
and administered via intra-peritoneal injection at a volume of 0.6 ml kg-1. 
4.3.2 Carbon-Fiber Microelectrodes (CFMs) 
CFMs were fabricated employing 7µm diameter carbon-fibers (Goodfellow 
Corporation, PA, USA) aspirated into glass capillaries (0.6 mm external diameter, 0.4 
mm internal diameter, A-M systems, Inc., Sequim, WA). A carbon-glass seal was formed 
using vertical micropipette puller (Narishige Group, Tokyo, Japan). The exposed length 
of the carbon fiber was trimmed to 150 µm under an optical microscope. Microelectrodes 




4.3.3 Data Collection 
Waveform generation, data acquisition and signal processing were achieved by a 
commercial potentiostat (Dagan corp.), custom-built hardware, software written in house 
using LabVIEW 2009 and interfacing a PCIe-6341 DAC/ADC card (National 
Instruments, Austin, TX). Custom built software was employed to drive the hardware and 
perform data analysis including background subtraction, signal averaging and digital 
filtering (Knowmad Technologies LLC, Tucson, AZ). All potentials are quoted with 
respect to Ag/AgCl reference electrodes, which were fabricated via electrodeposition of 
Cl- by holding a silver wire (A-M systems, WA) at 4.0 V for 5 s in 1 M HCl. All data 
represented with error bars represent the standard error of the mean (SEM). 
4.3.4 Data Analysis 
All the Current vs time data were extracted from custom made software. 
Histamine current was transferred to its concentration using 2.825 µM/nA factor. 
Conversion factor for serotonin was 11 nM/nA. Statistical differences were obtained 
using one-tailed Student’s t-tests on paired data sets. (p < 0.05 was taken as significantly 
different) 
4.3.5 Data Modeling 
Simulations were carried out in MatLab R2014a (MathWorks, Natick, MA, USA) 
using ODE solver ode23s, implemented on an iMAC with operating system OS X 










The left hand side is the rate of change of the extracellular histamine [eha]. The first term 
on the right side multiplies the fractional release, AH3(t), caused by autoreceptor 
inhibition by the firing rate, fireha(t), and the vesicular histamine concentration, [υha]. 
The remaining terms are reuptake into the terminal, Vu([eha]), leakage from the terminal, 
a1[cha], uptake into glial cells, Vug([eha]), and leakage from the glial cells, 










H  ------(2) 
The term AH3
5ht is the time course of fractional serotonin release caused by the H3 receptors 
on serotonin neurons. All other terms in equation 2 are analogous to the terms in equation 
1.  
4.3.6 Flow Injection Analysis 
Flow injection analysis (FIA) was used for in vitro analyses. CFMs were inserted 
into a flangeless short 1/8 nut (PEEK P-335, IDEX, Middleboro, MA) in order for 2 mm 
of the tip to be exposed outside of the nut. The microelectrode-containing nut was then 
fastened into a modified HPLC union elbow (PEEK 3432, IDEX, Middleboro, MA). The 
other end of the elbow union was fastened into the out-flowing stream of the FIA buffer 
and incorporation of the reference electrode and for a ‘waste’ flow stream by drilling into 
the union. In vitro experiments were carried out at 2 mL min-1 flow rate using syringe 
infusion pump (kd Scientific, model KDS-410, Holliston, MA). Starting at 5s, a 
rectangular pulse of analyte was introduced into the buffer stream for 10 s via a six-port 
HPLC loop injector (Rheodyne model 7010 valve, VICI, Houston, TX). In order to avoid 




4.3.7 Animal Surgeries 
Handling and surgery on male C57BL/6J mice weighing 20−25 g (Jackson 
Laboratory, Bar Harbor, ME) were in agreement with University of South Carolina Guide 
for the Care and Use of Laboratory Animals, approved by the Institutional Animal Care 
and Use. Urethane (25% dissolved in 0.9% NaCl solution, Hospira, Lake Forest, IL) was 
injected intraperitoneally (i.p) and once deep anesthesia was confirmed, animals were 
secured into a stereotaxic instrument (David Kopf Instruments, Tujunga, CA) and 
stereotaxic surgery was performed. A heating pad sustained mouse body temperature 
around 37 °C (Braintree Scientific, Braintree, MA). Stereotaxic coordinates were taken in 
reference to bregma. A Nafion modified CFM was in the PM (AP: −2.45, ML: +0.50, 
DV: −5.45 to −5.55.). A stainless steel stimulating electrode (diameter: 0.2 mm, Plastics 
One, Roanoke, VA) was positioned into the MFB (AP: -1.07, ML: +1.10, DV: −5.00). 
Biphasic pulse trains applied through a linear constant current stimulus isolator 
(NL800A, Neurolog, Medical Systems Corp., Great Neck, NY) provoked histamine 
efflux. The 60 Hz trains were 350 μA each phase, 2 ms in width, and 2 s in length. To 
determine the effects of different stimulation parameters on histamine and serotonin, 
stimulation frequency, width and amplitude were systematically altered. The time in 
between stimulations (2 minutes) was determined sufficient to produce negligible effects 
on serotonin and histamine in subsequent stimulations.  A Ag/AgCl reference electrode 







4.4 Results  
4.4.1 Simultaneous Measurements of Serotonin and Histamine 
In this experiment, we implanted a CFM in the PM of an anesthetized mouse and 
electrically stimulated the MFB. A representation of this experimental model, illustrating 
the relative positions of the working and stimulations electrodes can be found in Figure 
4.1Ai. Directly underneath this, in Figure 4.1Bi, is a raw data color plot showing the 
resultant electrochemical signal at the CFM. The interpretation of color plots is described 
elsewhere in detail 18. Concisely, background subtracted cyclic voltammograms collected 
at 10 Hz for 30 seconds are displayed as voltage (y-axis) vs. time (x-axis) and current 
(false color). The green bar directly under the color plot denotes the occurrence and 
duration of the electrical stimulation. Upon stimulation there are several events, typical of 
in vivo FSCV measurements whereby other electroactive species, pH changes and ionic 
fluxes affect the measurement 19,20. Of interest is the discrete event occurring at 0.3 V 
which is denoted by the horizontal dashed line and the blue star. A cyclic voltammogram 
(CV) extracted from the vertical dashed line through this event is displayed in Figure 
4.1Ci (solid line). The oxidation peak at 0.3 V shows excellent agreement with the 
oxidation peak extracted from an in vitro injection of histamine (dashed) normalized to 
maximum current and superimposed onto this in vivo CV. In our prior work, we showed 
electrochemically and pharmacologically that this event is histamine release 16. 
Histamine’s electro-oxidation scheme has not yet been described. It is likely that the peak 
at 0.3V occurs because of a proton transfer type oxidation between the aliphatic amine 




proton transfer oxidation, it follows that it should occur at a potential lower than observed 
for classic serotonin and dopamine electrooxidation (i.e. 0.6 - 0.8 V) 21. 
Figure 4.1. (Ai & Aii) The position of electrodes (stimulation and CFM) in mouse brain. 
(Bi & Bii) Representative color plots of the stimulated release of histamine and serotonin 
in the premammillary nucleus (PM) and stimulated release of serotonin in the substantia 
nigra (SNr) respectively. (Ci & ii) Superimposed cyclic voltammograms of in vivo and in 
vitro histamine and serotonin signals taken from vertical dashed lines in the PM. (Ciii) 
Comparison of normalized CVs of in vivo serotonin signals taken from vertical dashed 
lines in both PM and SNr. HA= histamine, 5-HT = serotonin. 
 
An additional event of interest occurs at around 0.7 V and is denoted by the 
horizontal dashed line and red heart. Because FSCV is background subtracted, ambient 
levels cannot be determined, thus according to the false color scale, this event signals a 
decrease in concentration. A CV collected at the vertical dashed line through this event is 
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presented in Figure 4.1Cii. A CV taken from an in vitro injection of serotonin was 
inverted on the current axis (to mimic a decrease in concentration), normalized to 
maximum current and superimposed (dashed) onto the in vivo CV. The good agreement 
between the peaks at 0.7 V strongly implies that this event is caused by serotonin. To 
further confirm this notion, we made a measurement of serotonin with this waveform via 
an experimental model of MFB stimulation and measurement in the substantia nigra pars 
reticulata (SNr) that we have well established for serotonin FSCV 22. This experimental 
model is depicted in Figure 4.1Aii and the color plot arising from the in vivo experiment 
is shown in Figure 4.1Bii. The stimulated serotonin event occurs at the same horizontal 
(potential) position on the color plot. The CV extracted from this color plot, inverted, 
normalized to maximum current and superimposed to the in vivo CV collected in the PM 
shows in excellent agreement in Figure 4.1Ciii.  
4.4.2 Serotonin Inhibition Following Histamine Release 
The event immediately following histamine release proceeds in the negative false 
color current direction. FSCV cannot determine basal concentrations (vide supra) thus 
one can only determine changes from ambient levels. This result, therefore, is indicative 
of a reduction in the ambient concentration of serotonin after stimulation. Figure 4.2A is 
a representative color plot showing simultaneous histamine release and serotonin 
inhibition in the PM upon MFB stimulation. Figure 4.2C-E shows serotonin and 
histamine concentrations with time for different stimulation parameters (dark solid lines 
= maximum responses and lighter dashed lines = lower responses) extracted from the 
horizontal dashed lines from the color plot (n=5 animals). The decrease in serotonin 




that serotonin inhibition may be dependent on histamine release. To probe this notion, we 
systematically altered stimulation parameters to assess whether the profile of histamine 
release affects serotonin inhibition. The dark solid line shows the maximum responses for 
the 60 Hz stimulation frequency in Figure 4.2C. 
Figure 4.2. (A) Representative color plot of the stimulated release of histamine and 
serotonin inhibition in the PM. (B) Correlation plot between [histamine] and [serotonin] 
for all stimulation parameters. (C) Averaged current vs. time traces along the two 
horizontal dashed lines of histamine and serotonin with respect to different stimulation 
frequencies (n=5). (D) Averaged current responses to various stimulation pulse widths of 
histamine and serotonin (n=5). I Averaged current responses to various stimulation 
amplitudes of histamine and serotonin (n=5). [HA] = [histamine], [5-HT] = [serotonin].  
 
The lighter colored dashed lines in Figure 4.2C shows the result of altering the 
stimulation frequency from 10 - 40 Hz (n=5 animals). There is a clear correlation 
between histamine release and the serotonin inhibition profiles. This is apparent in terms 
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of both time course (i.e. 10 Hz stimulation leading to lower, more prolonged histamine 
release and subsequent serotonin inhibition) and amplitude (higher level of histamine 
release corresponds to higher level of serotonin inhibition). This pattern holds true for 
stimulation pulse width and amplitude (Figure 4.2D and E) (n=5 animals). In Figure 
4.2B, the relationship between histamine release and serotonin inhibition was more 
formally explored by directly plotting amplitude of histamine release vs. amplitude of 
serotonin inhibition for the three stimulation parameters explored. We found a linear 
relationship (R2 = 0.757) connecting histamine release to serotonin inhibition for all three 
parameters explored. 
4.4.3 Mathematical Modeling of Serotonin and Histamine Co-regulation 
We needed to vary only three functions, fireha(t), AH3(t), and AH3
5ht(t), from 
equations 1 and 2 to obtain excellent model fits to our experimental data. Figures 4.3A 
and B show the model fits (dotted lines) to the experimental curves (solid lines) for 
control and 20 mg kg-1 thioperamide, respectively. Thioperamide selectively acts as an H3 
receptor (auto and hetero) antagonist on both histamine and serotonin pre synaptic 
neurons 23. In our model, the electrical stimulation is mimicked by raising  fireha(t) 
above its tonic level of 5 spikes/sec. Figure 4.3C shows fireha(t) vs. time that best fits 
the control and thioperamide experiments. fireha(t) returns to baseline at 9 seconds and 
the rates are higher after thioperamide.   
To fit the slow decline in histamine after stimulation, it was necessary to 
incorporate an autoreceptor function as per our previous serotonin model 12 Figure 4.3D 
shows fractional histamine release, AH3(t), as a function of H3 autoreceptors activation 




inhibition was AH3(t)= 0.7 up to 9 seconds, then dropped to AH3(t)= 0 up to 15 seconds 
(complete inhibition), and then returned to AH3(t)= 0.4 from 15 seconds to 30 seconds. 
For thioperamide, AH3(t)= 0.9, and the smallest fractional release is AH3(t) = 0.5. Our 
model shows that the H3 autoreceptor effect is delayed (starting at 9 seconds) and lasts 
throughout our file collection window (30 seconds). 
 
Figure 4.3. (A) [Histamine] vs. time plots comparing in vivo (solid traces) and the results 
of the mathematical model (large dots) in the control case. (B) [Serotonin] vs. time plots 
comparing in vivo (solid traces) and the results of the mathematical model (large dots) in 
the presence of thioperimide (20 mg kg-1) (C) Firing rate of the histamine neurons as a 
function of time in the two cases control (blue) and drug (green), respectively. (D) 
Assumed fractional release of histamine from the histamine neurons as a function of time 











































































We next modeled our serotonin curves.  Since the serotonin neurons are not 
stimulated, fire5ht(t)  remains at a tonic level of 5 spikes/sec. We varied AH3
5ht(t) (fraction 
of serotonin release permitted by the H3 receptors on serotonin neurons). For the control 
experiment, AH3
5ht(t) starts at 0.9, goes down to 0.45, and then returns to 0.9. For 
thioperamide, AH3
5ht(t) starts at 0.9, goes down to 0.36, and then returns to 0.8 at 30 
seconds (graphs not shown). As above, the H3 receptor effect is prolonged throughout file 
collection (> 60 seconds). 
4.4.4 H3 Receptor Mediated Inhibition of Serotonin 
Three different doses of thioperamide, an H3 receptor antagonist 
23, were 
administered to different groups of mice. This agent’s effects on histamine release and 
serotonin inhibition was observed 50 minutes after administration, which is a sufficient 
time period for thioperamide to exert its effects 24,25. The results are shown in Figure 4.4. 
Here, histamine before drug is displayed in blue and after drug in green, serotonin before 
drug is red, and after drug is orange. Error bars showing SEM (n=5 ± SEM) are lighter 
versions of these respective colors. 
Thioperamide, administered at 2 mg kg-1 caused a significant increase in the 
amplitude of histamine release from 7.5 ± 1.4 µM to 11.5 ± 1.4 µM (p = 0.004), but not 
in rate of histamine clearance (t1/2 from 11.5 ± 1.5 s to 14.3 ± 2.4 s, p = 0.07). The effects 
of 2 mg kg-1 on the amplitude and time course of serotonin inhibition were negligible. 
Maximum serotonin inhibition changed from 34.2 ± 7.5 nM to 37.5 ± 11.9 nM (p = 0.55), 





Figure 4.4. [Histamine] vs time traces are shown in blue and green for pre and post drug 
administration respectively. [Serotonin] vs time traces are shown in red and orange for 
before and after the drug. Error bars showing SEM (n=5 ± SEM) are lighter versions of 
these respective colors. (A) thioperamide 2 mgKg-1 (B) thioperamide 20 mgKg-1 (C) 
thioperamide 50 mgKg-1. [HA] = [histamine], [5-HT] = [serotonin]. 
 
Thioperamide administered at 20 mg kg-1 dose affected both the amplitude and 
clearance time of histamine response. Histamine elevated from 7.9 ± 2.1 µM to 11.9 ± 4.2 
µM (p = 0.03) and t1/2 from 14.7 ± 2.8 s to 19.6 ± 2.3 s (p = 0.02), but only the time 
course of the serotonin response (maximum inhibition from 38.8 ± 5.01 nM to 44.8 ± 4.5 
nM (p = 0.31). Furthermore, serotonin inhibition at 30 s increases from 16.5 ± 5.3 nM to 
37.7 ± 9.6 nM, (p = 0.002). At the highest dose, thioperamide greatly affected histamine 
release from 6.8 ± 1.9 µM to 14.3 ± 4.1 µM (p = 0.006) and reuptake such that histamine 
does not return to baseline during the 30 second file acquisition window. The effects on 


















68.2 ± 20.0 nM (p = 0.04), whereas, inhibition at 30 s enhanced from 24.4 ± 7.9 nM to 
65.9 ± 14.8 nM (p = 0.03). 
4.5 Discussion 
4.5.1 FSCV: A Powerful Tool for Simultaneous, Real-time Serotonin and 
Histamine Measurements 
FSCV at CFMs is a powerful tool for neurotransmitter analysis because of 
FSCV’s rapid, sensitive and selective analysis capabilities in addition to the minimally 
invasive dimensions of CFMs. A traditional drawback of FSCV is its limited in vivo 
analytical scope (measuring primarily dopamine) 26-28, which has been systematically 
challenged in recent years via advances to measure serotonin 10, adenosine 29, H2O2 
30 and 
gonadotropin-releasing hormone 31. We are primarily interested in deciphering the in vivo 
dynamics that regulate extracellular serotonin levels, and we were thus oriented towards 
histamine. There is a significant body of literature that suggests histamine inversely 
modulates serotonin in the brain 6,15. Many of these studies propose that dysregulations in 
histamine underlie disorders that are primarily considered to be serotonin mediated (e.g. 
depression) 32-34. In 2011 we described simultaneous histamine and serotonin 
measurements in the rat SNr 22. However, the FSCV peaks utilized to quantify histamine 
occurred at the anodic switching potential. These so called ‘switching peaks’ occur when 
spontaneous adsorption of analytes changes the electrical bilayer, hence capacitative 
current on the CFM. While switching peaks can be used to quantify histamine in a well-




vivo because other analytes that adsorb to the CFM provide identical, indistinguishable 
CVs 16. 
In 2015 we addressed the issue of selective in vivo histamine analysis by 
developing a detection waveform that displayed a distinct Faradaic-like peak 
corresponding to histamine oxidation. We successfully applied this waveform in vivo to 
selectively quantify histamine 16. In this study, we show that this novel waveform can 
simultaneously and selectively measure not only histamine, but also serotonin (vide 
infra), which greatly aids our interests in establishing how histamine modulates serotonin 
chemistry.  
4.5.2 MFB Stimulation Rapidly, Potently Inhibits Ambient Serotonin in the PM 
Figure 4.1 shows histamine release upon MFB stimulation in a hypothalamic 
region, the PM. We and others previously established this stimulation and measurement 
model to be robust and successful in evoking histamine 35,36 since the PM is home to a 
dense population of histamine cell bodies 36 and the region of the MFB that we stimulate 
contains histamine axons 37,38. The PM region also contains serotonin terminals 5,17, 
therefore we postulated that the PM seemed a promising area to study 
histamine/serotonin modulation, particularly because our data imply that the electrical 
stimulation does not evoke serotonin. This finding is supported by the presence of fewer 
serotonin axons in the anterior area of the MFB (our stimulation location) 39,40. 
Importantly, this model allows us to investigate histamine’s effects on serotonin 
chemistry in the absence of stimulated serotonin release. This type of measurement can 
be greatly facilitated in the future with the development of optogenetic tools that 




In accord with our postulation, in Figure 4.1, an event following the evoked 
histamine event by around 2 seconds is apparent. Via comparison of CVs collected in 
vitro and in vivo in the SNr (an area we have well established for serotonin FSCV) 21,41, 
we can electrochemically verify this second event to be caused by serotonin. The small 
deviation in the peak positions in Figure 4.1cii is typical when comparing in vivo and in 
vitro responses and is likely due to differences in ohmic drop between in vitro and in vivo 
preparations. Of great interest, our data indicate that the serotonin levels are decreasing 
in response to the stimulation. Because FSCV is a background subtracted method, 
ambient levels cannot be established therefore the conclusion of this data is that MFB 
stimulation inhibits ambient serotonin activity by around 40 nM. FSCV most commonly 
observes increased neurotransmitter activity, thus our experiment represents an exciting 
opportunity to study inhibition of ambient activity.  
We next hypothesize that this inhibition is, at least partially, mediated by 
histamine based on prior histamine/serotonin modulation studies 6,15. In the next sections 
we take experimental, mathematical and pharmacological approaches towards this 
hypothesis. 
4.5.3 Histamine Mediates Serotonin Inhibition in the PM 
i) Serotonin Inhibition is Concentration and Time Correlated to Histamine Release 
To show that histamine, rather than another result of MFB stimulation inhibits 
serotonin in the PM, we systematically altered our stimulation parameters to change the 
profile of histamine release. Figure 4.2 shows excellent agreement between the time 
course and amplitude of histamine release and serotonin inhibition. The raw data in 




histamine release, and the Figure 4.2B highlights this correlation more formally by 
plotting maximum histamine release amplitude vs. maximum serotonin inhibition 
amplitude. The linear relationship between histamine and serotonin with all stimulation 
parameters is strong evidence for chemical rapport between these two molecules in the 
PM. 
ii) Mathematical Modeling of Serotonin Inhibition Necessitates an Autoreceptor 
Function. 
The power of interpreting experimental data through mathematical models is the 
ability to test a number of physiological hypotheses. Above, we hypothesized that 
serotonin inhibition is histamine mediated, we now test this notion mathematically. Our 
model necessitates ambient (basal) histamine and serotonin levels which we are not yet 
able to determine with FSCV. For histamine, a value of 1.5 μM was chosen, because our 
data show that after stimulation histamine levels fall 1 μM or more below baseline 
(Figures 4.2, 3, 4). Similarly, for the same reason we chose 65 nM as the basal 
concentration of serotonin in the extracellular space. We found that we could fit the data 
closely via simple manipulations of H3 heteroreceptor and autoreceptor strengths in our 
model. H3 heteroreceptors on serotonin terminals 
15,42 have previously been postulated to 
inhibit serotonin 6. Our model supports this hypothesis, particularly given that is unlikely 
that the serotonin inhibition we observe is attributable to other slower mechanisms such 







iii) H3 receptor Mediation of Serotonin Inhibition 
Given the results of our mathematical modeling and the large body of prior work 
implicating H3 heteroreceptors as an inhibitory mechanism for serotonin 
15,42 we decided 
to probe H3 receptor mediation of serotonin. Figure 4.4 shows the results of systemically 
administering varying doses of a potent H3 receptor antagonist, thioperamide, to different 
mice. The low dose (2 mg kg-1) increased the amplitude of histamine release (consistent 
with prior studies with dopamine and D2 autoreceptor antagonism) 43,44, but has no 
significant effect on serotonin. This phenomenon is not difficult to explain because the 
serotonin response is controlled by dual mechanisms of a) now increased histamine 
available to antagonize H3 receptors and b) a larger percentage of H3 receptors 
antagonized on serotonin neurons. The overall result is a manifestation of two opposing 
effects that cancel each other out. 
The 20 mg kg-1 dose had effects on both histamine release and clearance 
(reuptake effects have been previously been seen with serotonin autoreceptor 
antagonism) (Wood et al. 2014). The effect on the magnitude of serotonin inhibition was 
not significant, however it seems that the prolonged histamine in the synapse is 
outcompeting thioperamide for H3 receptors on serotonin neurons to create prolonged 
serotonin inhibition (> 60 seconds).  
H3 heteroreceptors are likely more localized in the synapse, because of their 
position on serotonin terminals 45 than are H3 autoreceptors on presynaptic histamine 
neurons. Autoreceptors are generally found outside of the direct synaptic space, asserting 
inhibition when a concentration threshold is reached 46. The inhibition constant (Ki) of 





47,48. However, after stimulation histamine concentrations are very high in 
the direct synaptic space (likely reaching mMs based on prior dopamine models) 49 and 
fall off exponentially with distance. Because the thioperamide concentration is assumed 
to be homogenous throughout this brain region, the histamine most certainly outcompetes 
thioperamide for H3 heteroreceptors on serotonin neurons. This notion is made apparent 
by the largest dose (50 mg kg-1) of thioperamide which created significant and long 
lasting serotonin inhibition. 
In sum, we showcased the power of FSCV for simultaneous measurements of 
histamine and serotonin the PM. We showed that MFB stimulation released histamine but 
created a potent inhibition of serotonin. Voltammetrically, mathematically and 
pharmacologically we showed serotonin inhibition was dependent on histamine release, 
via an H3 receptor mediated mechanism. Our approach signals a powerful advancement 
in FSCV technology that will facilitate the systematic study of histamine and serotonin 
dynamics in the variety of different brain processes involving these two molecules. 
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SELECTIVE SEROTONIN REUPTAKE INHIBITORS BLOCK 
HISTAMINE REUPTAKE VIA MONOAMINE TRANSPORTERS; A 





Histamine plays many important roles in the brain and irregularities in this 
messenger have been implicated in many disorders1-5. Despite this association, the few 
central nervous system (CNS) histamine targeting therapeutics show inadequate 
efficacy1-3.  This is primarily because little is known about histamine’s roles as a 
neuromodulator, other than controlling monoamines via H3 receptors
6-8. The relationship 
between histamine and serotonin is of particular interest to our lab since we chiefly study 
in vivo serotonin regulation mechanisms.  
Histamine is released into the synapse via exocytosis and thought to be primarily 
enzymatically degraded by histamine N-methyltransferase (HNMT)9-12. While there is 
evidence for partial histamine reuptake into synaptosomes13,14 and astrocytes15,16, a 
transporter for histamine has not been identified17,18. Given that HNMT has been found to 
be exclusively intracellular,19,20 it seems incongruent that there would not exist an active 
histamine reuptake mechanism. We therefore sought to clarify this inconsistency. 
We recently described a fast-scan cyclic voltammetry (FSCV) technique that can 
simultaneously measure in vivo histamine and serotonin with sub-second temporal 
resolution at carbon fiber microelectrodes (CFMs). In this paper we investigated 
histamine reuptake by dopamine transporters (DATs), serotonin transporters (SERTs), 
norepinephrine transporters (NETs) and organic cation transporters (OCTs). The rationale 
here originated from our prior work where we mathematically modeled histamine 
responses and found that the clearance curve could be fit with first order Michaelis-
Menten kinetics,14,6 commonly seen for dopamine21 and serotonin22,23 active reuptake. 




dopamine, serotonin and norepinephrine between monoamine transporters24. Taken 
together, these findings provide a compelling platform for monoamine transporters in 
synaptic histamine removal. 
By electrically stimulating histamine release in the mouse posterior hypothalamus 
(PH) we observe the effects of pharmacological manipulations on the DAT, NET, SERT 
and OCTs on histamine reuptake. First, we show the lesion left by the CFM in 
histological section for all the experiments, attesting to the high accuracy of our surgical 
procedure. Second, the in vivo histamine response is highly reproducible between groups 
of animals. Third, vehicle injections do not substantially change control responses. 
Fourth, the histamine clearance profile is not altered by DAT inhibition. Fifth, 
desipramine-mediated NET inhibition and SERT inhibition via 3 different SSRIs exert 
varying degrees of reuptake inhibition on histamine. Despite the heterogeneous response 
to these agents, one commonality between them is that they all have the capacity to 
inhibit OCTs. Thus, OCTs are blocked, generating the most dramatic decrease in the rate 
of histamine reuptake. Collectively, our results suggest an active reuptake mechanism for 
histamine, likely primarily via the OCTs. This information is important for improving 
development and efficacy of neuropharmaceuticals for histamine during 
pathophysiology. 
5.2 Materials and Methods 
5.2.1 Pharmacological Agents 
Escitalopram oxalate, citalopram hydrobromide, sertraline hydrochloride, GBR 




from Sigma-Aldrich, MO, USA. All drugs were dissolved in 9% sterile saline solutions 
and administered via i.p injection at 0.1 20 mL/g except for sertraline and decynium-22, 
which were dissolved in DMSO at 5% concentration in sterile saline.   
5.2.2 Carbon-Fiber Microelectrodes (CFMs) 
Carbon-fibers (Goodfellow Corporation, PA, USA) of 7 µm diameter were 
aspirated into glass capillaries (0.6 mm external diameter, 0.4 mm internal diameter, A-M 
Systems, Inc., Sequim, WA) to fabricate the CFMs. A carbon-glass seal was formed 
using vertical micropipette puller (Narishige Group, Tokyo, Japan). The exposed length 
of the carbon-fiber was trimmed to 150 µm under an optical microscope. CFMs were 
electroplated with Nafion. 
5.2.3 Data Collection 
A commercially available potentiostat (Dagan Corporation, Minneapolis, MN) 
and custom build hardware interfacing a PCIe-6341 DAC/ADC card (National 
Instruments, Austin, TX) were used for waveform generation, data acquisition, and signal 
processing. Custom built software, written in-house using LabVIEW 2009, was used to 
drive the hardware and perform data analysis including background subtraction, signal 
averaging and digital filtering (Knowmad Technologies LLC, Tucson, AZ). All potentials 
were measured with respect to Ag/AgCl reference electrode. The reference electrode was 
fabricated via electrodeposition of Cl- by holding a silver wire at 5.0 V for 5 s in 1 M 






5.2.4 Data Analysis 
All current vs. time curves and cyclic voltammograms (CVs) were collected with 
software made in-house. Current was converted to concentration by using standard 
calibration factors, for histamine = 2.82 µM/nA and serotonin = 11 nM/nA. One-tailed 
Student’s t-tests on paired data set were used to determine statistical significance (p < 
0.05 was taken as significantly different). 
5.2.5 Animal Surgeries 
Handling and surgery on male C57BL/6J mice weighing 20−25 g (Jackson 
Laboratory, Bar Harbor, ME) was in agreement with the University of South Carolina’s 
Guide for the Care and Use of Laboratory Animals, approved by the Institutional Animal 
Care and Use. Urethane (25% dissolved in 0.9% sterile saline solution, Hospira, Lake 
Forest, IL) was injected i.p and once deep anesthesia was confirmed, animals were 
secured into a stereotaxic instrument (David Kopf Instruments, Tujunga, CA) and 
stereotaxic surgery was performed. A heating pad was used to sustain mouse body 
temperature around 37 °C (Braintree Scientific, Braintree, MA). Stereotaxic coordinates 
were taken in reference to bregma. A Nafion plated CFM was placed in the PH (AP: 
−2.45, ML: +0.50, DV: −5.45 to −5.55.). A stainless-steel stimulating electrode 
(diameter: 0.2 mm, Plastics One, Roanoke, VA) was positioned into the MFB (AP: -1.07, 
ML: +1.10, DV: −5.00). Biphasic pulse trains were applied through a linear constant 
current stimulus isolator (NL800A, Neurolog, Medical Systems Corp., Great Neck, NY) 
to provoke histamine efflux. The 60 Hz trains were 360 μA each phase, 2 ms in width, 




Ag/AgCl reference electrode (constructed by plating Cl- ions onto an Ag wire) which was 
implanted into the opposite brain hemisphere. 
5.2.6 Histology 
To verify the placement of the CFMs in vivo, after experimentation the CFM was 
used to create a small lesion in the recording site by applying a constant potential (20 V 
for 10 s)25. Following experiments, mice were sacrificed and brains were removed from 
the skull and stored in 10% paraformaldehyde solution in phosphate buffered saline 
(PBS). The brains were then stored in 15% sucrose until they sank. Brains were then 
flash-frozen, sectioned into 20 µm slices using a cryostat (Cryotome FSE, Thermo 
Scientific, Kalamazoo, MI) and mounted on glass slides. Finally, brain slices were 
stained with 0.2% crystal violet and photographed under an optical microscope.      
5.3 Results and Discussion 
5.3.1 Histology 
Figure 5.1 shows a representative image showing the lesion of the CFM (A) and 
the stimulating electrodes (B) circled in blue. In Figure 5.1C, the location of all the 
electrodes utilized in this study (one electrode per mouse) are shown in slices between 







Figure 5.1. CFMs and stimulating electrode placements in PH and MFB respectively. 
(A) CFM lesion which is denoted by a blue circle. (B) Left hemisphere is a diagram 
illustrating intended placement of MFB, and right hemisphere shows the actual placement 









5.3.2 Selective sub-second neurochemical detection of histamine  
Upon electrical stimulation of the MFB, histamine was evoked in the PH and this 
was verified with FSCV recording, as visualized in the color plot in Figure 5.2. Figure 
5.2A-F shows representative color plots, cyclic voltammograms (CVs) and averaged 
[histamine] vs. time responses in groups of animals that served as controls for subsequent 
pharmacology experiments (animal groups A to F). The interpretation of color plots is 
described elsewhere in detail6,26. Briefly, background subtracted cyclic voltammograms 
collected at 10 Hz for 30 seconds are displayed as voltage (y-axis) vs. time (x-axis) and 
current (false color scale). The green bar directly underneath the color plot denotes the 
occurrence and duration of the electrical stimulation. Upon electrical stimulation, there 
are several non- faradaic events, due to other electroactive species, pH changes and ionic 
fluxes27,28 which occur at the switching potentials. Distinct histamine oxidation occurs at 
0.3 V, denoted by the horizontal dashed line. 
CVs for histamine detection for each drug were extracted from each color plot at 
the vertical dashed line through the event, which is represented by a yellow star, and 
illustrated in middle column of the Figure 5.2 (Cyclic Voltammograms). The oxidation 
peak at 0.3 V (blue bar named as histamine) proves the selective histamine detection. 
Figure 5.2 right column shows the electrically evoked average histamine responses, 
which are extracted from horizontal dashed line named HA from each color plot. This 







Figure 5.2. The representative color plots, cyclic voltammograms (CVs) and evoked 
histamine traces for control experiments in different sets of animal groups 1 to 6. Left 
column shows color plots. The middle column illustrates CVs that were extracted from 
each color plot at the vertical dashed line (denoted by the yellow star). Right column 
shows the average control [histamine] vs time traces for each drug category (n=5 ± 
SEM). Shaded region around the trace represents the SEM. Green bars underneath each 
color plot and each trace in the right column represent the stimulation. Blue vertical bars 
in the middle column highlights the histamine oxidation peak.  
 




5.3.3 Effect of Vehicle  
 
Figure 5.3. Top panel - [histamine] vs. time traces are shown in blue and green for pre 
and post-vehicle administration respectively. Bottom panel - [serotonin] vs. time traces 
are shown in red and orange for before and after the vehicle respectively. Error bars 
showing SEM (n=5 ± SEM) are lighter versions of these respective colors. (A) 5% 
DMSO and (B) Saline 
 
In the proceeding pharmacological manipulations, either 5% DMSO or sterile 
saline were used to dissolve active agents. Therefore, DMSO and saline were 
administered to different groups of mice to test the effects of vehicle on the signal. 
Figure 5.3A shows the average concentration vs. time traces of histamine (top panel), we 
also measured serotonin (bottom panel). This inverse serotonin response illustrates the 
reduction of ambient serotonin concentration via H3 receptor activation by evoked 
histamine, as we previously showed. Histamine and serotonin responses after 50 minutes 
of 5% DMSO administration (i.p.) are presented in green and orange traces respectively 





5.3.4 OCT-mediated histamine uptake: pharmacological evidence 
 
Figure 5.4. Comparison of histamine and serotonin responses after monoamine 
transporter inhibitors. (A) GBR 12902 (15 mg/kg) (B) desipramine (15 mg/kg) (C) 
escitalopram (10 mg/kg) (D) citalopram (5 mg/kg) I sertraline (10 mg/kg). (F) decynium-
22 (0.1 mg/kg). In each drug category, average histamine vs. time traces collected every 
10 minutes for 60 minutes are shown in 3D plots (left panel). The right panel shows the 
[histamine] vs. time traces for control in blue and 50 minutes post-drug in green. 
[serotonin] vs. time traces are shown in red and orange for control and post-drug 
respectively. Stimulation period is represented by a green bar between histamine and 
serotonin responses. Error bars represents the SEM (n=5 ± SEM) in lighter versions of 





Next, we investigated histamine reuptake via 4 monoamine transporter proteins. 
Six different transporter inhibitor drugs, GBR 12902 (15 mg/kg), desipramine (15 
mg/kg), escitalopram (10 mg/kg), citalopram (5 mg/kg), sertraline (10 mg/kg) and 
decynium-22 (0.1 mg/kg), were injected (i.p.) into different mice. Histamine and 
serotonin responses were measured every 10 minutes, for 60 minutes, after drug 
administration. Figure 5.4A-left shows a 2D representation of a 3D plot of histamine 
responses upon stimulation with time after drug. The first solid black trace in the 3D plot 
represents the pre-drug [histamine] response. [Histamine] responses collected every 10 
minutes after drug administration, for 60 minutes, are stacked next to one another and 
given a false color. The x-axis represents 30 seconds for an individual file, y-axis 
represents 60 minutes after the drug administration and z-axis represents [histamine]. 
This 2D plot allows for visualization of the effects of the time course of an agent’s effects 
on histamine reuptake. The right panel in Figure 4A shows averaged histamine traces 
before drug (blue) and 50 minutes after the drug (green) and averaged serotonin traces 
before drug in red and after drug in orange between animals (n=5 ± SEM). Figure 4B, C, 
D, E, and F demonstrate the effects of desipramine (15 mg/kg), escitalopram (10 mg/kg), 
citalopram (5 mg/kg), sertraline (10 mg/kg) and decynium-22 (0.1 mg/kg) respectively. 
DATs 
High levels of histamine decarboxylase have been found in dopamine-rich regions 
such as the striatum29. In addition, histamine receptors are heavily expressed in the 
nucleus accumbens18,30, an area extensively studied for dopamine transmission31,32. There 
is also evidence for histaminergic modulation of dopamine transmission in the striatum 




actions of dopamine and histamine, we first tested whether DATs mediate histamine 
reuptake. A potent DAT inhibitor, GBR 1290935, did not lead to significant changes in 
histamine reuptake as shown in Figure 4A. This observation suggested that there is no 
involvement of DAT in histamine reuptake in the PH. 
NETs 
Recent studies have shown the existence of NETs in rat posterior and anterior 
hypothalamic36,37 area as well as the regulation of norepinephrine via H3 receptors
38. 
Together this evidence suggests possible comodulation of norepinephrine and histamine. 
In comparison to DAT, the NET inhibitor, desipramine, slightly decelerated the reuptake 
of histamine when compared to control animals (Figure 4B). An interesting finding is 
that NET blockage enhanced histamine-mediated serotonin firing inhibition. The 
antidepressant-like effects of this tricyclic antidepressant drug suggest the regulation of 
serotonergic system through SERTs24,39,40.  Extracellular histamine also plays a 
significant role in regulating the serotonin release via H3 receptors. Hence, resulting in 
greater inverse regulation of serotonin via H3 activation. 
SERTs 
We and others have shown that histamine modulates serotonin transmission8,41. 
Serotonin is reuptaken with high efficiency by SERTs 42. SERTs are localized in some of 
the highest numbers in the PH43,44. Given the close modulatory relationship between 
histamine and serotonin, we next decided to study whether SERT inhibition exerts an 
effect on histamine clearance. Escitalopram45 and citalopram46 (selective serotonin 
reuptake inhibitors (SSRIs)) substantially slowed histamine reuptake and lead to a 




shown in Figure 5.4D & E. However, sertraline47, also an SSRI, had minimal effects on 
the histamine signal. Thus, the discrepancy between the three SSRIs proposes that SERT 
may not be the primary reuptake mechanism for histamine. Like desipramine, 
escitalopram and citalopram both have high affinity for the OCT but sertraline does 
not48,49. We thus turned to the OCTs. 
A point to note is that SERT inhibitors (escitalopram and citalopram) exhibit 
slightly less inhibition of serotonin with respect to controls (Figure 5.4 D & E). The 
enhanced release of serotonin by SERT inhibitors45 overcomes the inhibition of serotonin 
via H3 receptors
6 and makes the inverse modulation of serotonin less but insignificant in 
the post-drug condition. 
OCTs 
We inhibited the OCT reuptake mechanism via decynium-2249 in a final set of 
mice. Decynium-22 demonstrated the most significant effect on histamine clearance, as 
shown in Figure 4F, suggesting OCT mediated histamine reuptake. Furthermore, post-
drug inverse modulation of serotonin illustrated insignificant inhibition when compared 
to the control response (Figure 4F). This may be due to the bidirectional effects of 
elevated extracellular serotonin by inhibiting the OCT-mediated serotonin uptake48-50 and 
the serotonin inhibition via histamine6.     
Conclusion 
Histamine is a vital monoamine neurotransmitter which plays a significant role in 
the brain, but histamine’s reuptake mechanism is less studied. This electrochemical and 




histamine’s reuptake mechanism.  The histamine clearance profile was not affected by 
DAT inhibition. Whereas, NET and SERT inhibition demonstrated an inconsistency in 
reuptake inhibition on this messenger. Because of the NETs and SERTs inhibitory 
agents’ ability to inhibit OCTs, we finally, blocked the OCTs, which in turn showed the 
largest decrease in the histamine reuptake rate. Collectively, this work suggests an OCT 
mediated histamine reuptake mechanism in the brain. These novel discoveries illustrate 
the actions of monoamine transporters on histamine neurodynamics and offer new insight 
into histamine targeting therapeutic strategies. 
5.4 References 
(1) Panula, P.; Yang, H. Y.; Costa, E. Proceedings of the National Academy of 
Sciences of the United States of America 1984, 81, 2572. 
(2) Panula, P.; Rinne, J.; Kuokkanen, K.; Eriksson, K. S.; Sallmen, T.; Kalimo, H.; 
Relja, M. Neuroscience 1998, 82, 993. 
(3) Panula, P.; Nuutinen, S. Nature reviews. Neuroscience 2013, 14, 472. 
(4) Haas, H. L.; Sergeeva, O. A.; Selbach, O. Physiological reviews 2008, 88, 1183. 
(5) Rinne, J. O.; Anichtchik, O. V.; Eriksson, K. S.; Kaslin, J.; Tuomisto, L.; Kalimo, 
H.; Röyttä, M.; Panula, P. Journal of Neurochemistry 2002, 81, 954. 
(6) Samaranayake, S.; Abdalla, A.; Robke, R.; Nijhout, H. F.; Reed, M. C.; Best, J.; 
Hashemi, P. J Neurochem 2016, 138, 374. 
(7) Schlicker, E.; Betz, R.; Göthert, M. Naunyn-Schmiedeberg's Arch Pharmacol 




(8) Threlfell, S.; Cragg, S. J.; Kallo, I.; Turi, G. F.; Coen, C. W.; Greenfield, S. A. 
The Journal of neuroscience : the official journal of the Society for Neuroscience 2004, 
24, 8704. 
(9) White, T. The Journal of physiology 1960, 152, 299. 
(10) Schayer, R. W.; Reilly, M. A. The Journal of pharmacology and experimental 
therapeutics 1973, 184, 33. 
(11) Pollard, H.; Bischoff, S.; Schwartz, J. C. The Journal of pharmacology and 
experimental therapeutics 1974, 190, 88. 
(12) Takemura, M.; Imamura, I.; Mizuguchi, H.; Fukui, H.; Yamatodani, A. Life 
sciences 1994, 54, 1059. 
(13) Barnes, W. G.; Hough, L. B. J Neurochem 2002, 82, 1262. 
(14) Sakurai, E.; Sakurai, E.; Oreland, L.; Nishiyama, S.; Kato, M.; Watanabe, T.; 
Yanai, K. Pharmacology 2006, 78, 72. 
(15) Huszti, Z. Inflammation research : official journal of the European Histamine 
Research Society ... [et al.] 2003, 52 Suppl 1, S03. 
(16) Huszti, Z.; Prast, H.; Tran, M. H.; Fischer, H.; Philippu, A. Naunyn 
Schmiedebergs Arch Pharmacol 1998, 357, 49. 
(17) Hough, L. B. Progress in neurobiology 1988, 30, 469. 
(18) Brown, R. E.; Stevens, D. R.; Haas, H. L. Progress in neurobiology 2001, 63, 
637. 
(19) Nishibori, M.; Tahara, A.; Sawada, K.; Sakiyama, J.; Nakaya, N.; Saeki, K. The 
European journal of neuroscience 2000, 12, 415. 




(21) Walters, S. H.; Robbins, E. M.; Michael, A. C. ACS Chem Neurosci 2015, 6, 
1468. 
(22) Wood, K. M.; Zeqja, A.; Nijhout, H. F.; Reed, M. C.; Best, J.; Hashemi, P. 
Journal of Neurochemistry 2014, 130, 351. 
(23) Jones, S.; John, C. In Electrochemical Methods for Neuroscience; CRC Press: 
2006, p 49. 
(24) Gould, G. G.; Hensler, J. G.; Burke, T. F.; Benno, R. H.; Onaivi, E. S.; Daws, L. 
C. J Neurochem 2011, 116, 291. 
(25) Park, J.; Kile, B. M.; Wightman, R. M. The European journal of neuroscience 
2009, 30, 2121. 
(26) Michael, D. J.; Joseph, J. D.; Kilpatrick, M. R.; Travis, E. R.; Wightman, R. M. 
Analytical Chemistry 1999, 71, 3941. 
(27) Jones, S. R.; Mickelson, G. E.; Collins, L. B.; Kawagoe, K. T.; Wightman, R. M. 
Journal of neuroscience methods 1994, 52, 1. 
(28) Takmakov, P.; Zachek, M. K.; Keithley, R. B.; Bucher, E. S.; McCarty, G. S.; 
Wightman, R. M. Anal Chem 2010, 82, 9892. 
(29) Krusong, K.; Ercan-Sencicek, A. G.; Xu, M.; Ohtsu, H.; Anderson, G. M.; State, 
M. W.; Pittenger, C. Neuroscience letters 2011, 495, 110. 
(30) Pillot, C.; Heron, A.; Cochois, V.; Tardivel-Lacombe, J.; Ligneau, X.; Schwartz, 
J. C.; Arrang, J. M. Neuroscience 2002, 114, 173. 
(31) Jones, S. R.; Garris, P. A.; Wightman, R. M. The Journal of pharmacology and 




(32) Cheer, J. F.; Heien, M. L. A. V.; Garris, P. A.; Carelli, R. M.; Wightman, R. M. 
Proceedings of the National Academy of Sciences of the United States of America 2005, 
102, 19150. 
(33) Schlicker, E.; Fink, K.; Detzner, M.; Göthert, M. Journal of Neural Transmission 
/ General Section JNT 1993, 93, 1. 
(34) Galosi, R.; Lenard, L.; Knoche, A.; Haas, H.; Huston, J. P.; Schwarting, R. K. 
Neuropharmacology 2001, 40, 624. 
(35) John, C. E.; Jones, S. R. Neuropharmacology 2007, 52, 1596. 
(36) Pau, K. Y.; Lee, C. J.; Cowles, A.; Yang, S. P.; Hess, D. L.; Spies, H. G. Journal 
of neuroendocrinology 1998, 10, 21. 
(37) Hope, S. I.; Schmipp, J.; Rossi, A. H.; Bianciotti, L. G.; Vatta, M. S. 
Neurochemistry international 2008, 53, 207. 
(38) Flik, G.; Folgering, J. H.; Cremers, T. I.; Westerink, B. H.; Dremencov, E. 
Journal of molecular neuroscience : MN 2015, 56, 320. 
(39) Charney, D. S.; Heninger, G. R.; Sternberg, D. E. Archives of general psychiatry 
1984, 41, 359. 
(40) Zhao, Z.; Zhang, H.-T.; Bootzin, E.; Millan, M. J.; O’Donnell, J. M. 
Neuropsychopharmacology : official publication of the American College of 
Neuropsychopharmacology 2009, 34, 1467. 
(41) Hashemi, P.; Dankoski, E. C.; Wood, K. M.; Ambrose, R. E.; Wightman, R. M. 




(42) Lin, K. J.; Yen, T. C.; Wey, S. P.; Hwang, J. J.; Ye, X. X.; Tzen, K. Y.; Fu, Y. K.; 
Chen, J. C. Journal of nuclear medicine : official publication, Society of Nuclear 
Medicine 2004, 45, 673. 
(43) Borgers, A. J.; Alkemade, A.; Van de Giessen, E. M.; Drent, M. L.; Booij, J.; 
Bisschop, P. H.; Fliers, E. EJNMMI Research 2013, 3, 34. 
(44) Borgers, A. J.; Koopman, K. E.; Bisschop, P. H.; Serlie, M. J.; Swaab, D. F.; 
Fliers, E.; la Fleur, S. E.; Alkemade, A. Frontiers in Neuroscience 2014, 8, 106. 
(45) Wood, K. M.; Hashemi, P. ACS Chemical Neuroscience 2013, 4, 715. 
(46) Dankoski, E. C.; Carroll, S.; Wightman, R. M. Journal of Neurochemistry 2016, 
136, 1131. 
(47) Pyakurel, P.; Privman Champaloux, E.; Venton, B. J. ACS Chemical 
Neuroscience 2016, 7, 1112. 
(48) Wang, K.; Sun, S.; Li, L.; Tu, M.; Jiang, H. Progress in neuro-
psychopharmacology & biological psychiatry 2014, 53, 90. 
(49) Zhu, H. J.; Appel, D. I.; Grundemann, D.; Richelson, E.; Markowitz, J. S. 
Pharmacological research 2012, 65, 491. 
(50) Horton, R. E.; Apple, D. M.; Owens, W. A.; Baganz, N. L.; Cano, S.; Mitchell, N. 
C.; Vitela, M.; Gould, G. G.; Koek, W.; Daws, L. C. The Journal of neuroscience : the 







HISTAMINERGIC MODULATION OF SEROTONIN DURING 





Neuroinflammation is garnering increasing interest for its potential role in the 
pathology of many diseases and is commonly marked by increases in biomarkers such as 
proinflammatory cytokines1-3. In addition, recent studies have shown elevated brain 
histamine levels during neuroinflammation2,4. Neuroinflammation can originate from 
infections, brain injuries, viruses like human immune deficiency virus (HIV-1) and many 
other neurological disorders. Histamine is a monoamine neurotransmitter that regulates 
important brain functions and modulates other neurotransmitters like serotonin5-10. These 
monoamine neurotransmitters, including histamine and serotonin, are frequently 
implicated in the neurological disorders which are comorbid with neuroinflammation10-12. 
The lack of knowledge on the actions of the brain’s chemical messengers during 
inflammation seen with certain brain disorders makes the pathology difficult to properly 
elucidate. 
Neuroinflammation is an important symptom in HIV and in the rat HIV-1 Tg 
disease model. Recent studies have shown that HIV-1 Tg rats exhibit elevated levels of 
proinflammatory cytokines (INF-γ, TNF-α, and IL-1β), which are key biomarkers of 
inflammation13. In addition, the viral protein glycoprotein gp120 binds to the chemokine 
receptor, which exists in many of the cells present in the central nervous system, 
including neurons14,15. The neurotoxic effects of gp120 include induction of apoptosis 
and neural injury16 and can result in neuroinflammation during the adolescent period of 
the HIV-1 Tg rat’s life. Therefore, HIV-1 Tg is an excellent animal model to study 




This disease model has shown a trend toward increased anxiety-like behavior17,18 
as shown by open-field, general locomotor activity, and motivated behavior tests. 
Additionally, social interaction, novel stimulus and forced swim tests have revealed that 
HIV-1 Tg rats exhibit elevated depressive-like behaviors18. These observations are of 
particular interest as serotonin is the transmitter primarily implicated in depression and 
anxiety19,20. Given that histamine release is associated with local peripheral inflammation, 
and given we find that histamine inversely regulates serotonin in the brain, an important 
question follows: Is histamine involved in neuroinflammation and if so, how do 
alterations in histamine affect serotonin? We will ask these questions in the HIV-1 Tg rat.  
In this study, we employed our dual histamine/serotonin measurement strategy to 
investigate histaminergic regulation of serotonin in HIV-1Tg rats. To accomplish this 
task, we positioned the carbon fiber microelectrodes (CFMs) in the rat posterior 
hypothalamus (PH) and the stimulation electrode in the medial forebrain bundle (MFB). 
We found that histamine release was elevated in the disease model resulting in increased 
serotonin inhibition. We hypothesized that this elevated histamine would suppress 
evoked serotonin release. To test this hypothesis, we positioned another CFM in the 
prefrontal cortex (PFC) to investigate the stimulated release of serotonin. HIV-1 Tg rats 
were shown to have attenuated serotonin release with respect to control animals. Our 
results imply that histamine may play an important role in this regard. Collectively, this 
study works toward characterizing the importance of histamine’s role in controlling the 
serotonin release during disease states marked by neuroinflammation. 






Male and female F344 rats (n=17) and HIV-1 Tg rats (n=17) (Harlan 
Laboratories, Indianapolis, Indiana) were commercially ovariectomized and pair-housed 
by genotype.  Food and water were provided ad libitum throughout the experiment.  
Animals were kept in an AALAC-accredited facility at 21 +/- 2 C, 50% +/- 10% relative 
humidity, in a 12-hr light-dark cycle with lights on at 07:00h.  All experiments were 
performed according to the National Institute of Health guidelines for AAALAC 
accredited facilities.  All behavioral testing was conducted during the animal’s light 
cycle.  The research protocol was approved by the Institutional Animal Care and Use 
Committee (IACUC) of the University of South Carolina, Columbia, SC, under animal 
assurance number A3049-01. 
6.2.2 Carbon fiber microelectrodes (CFMs) 
 CFMs were fabricated according to Samaranayake et. al.,21.  In brief, 7 um-
diameter carbon fibers (Goodfellow Inc, Coraopolis, PA) were aspirated into glass 
capillary tubes (OD 0.6 mm, ID 0.4 mm, A-M Systems INC, Sequim, WA).  A vertical 
pipette puller was used to seal the carbon fiber to the capillary tube (Narishige Group, 
Tokyo, Japan).  The carbon fiber was then trimmed to 150 µm under a low-power light 






6.2.3 Animal Surgery 
Before surgery, animals were anesthetized using 2-3% sevoflurane inhalant 
(Abbot Laboratories, North Chicago, IL ). Once the animal was fully anesthetized, it was 
placed in the stereotaxic apparatus, and the head was leveled with respect to bregma 
(David Kopf Instruments, Tujunga, CA).  A heating pad (37 0C) was placed under the 
animal throughout the course of the experiment. CFMs were placed to PFC (AP: +2.6, 
ML: +0.6, DV: -4.7) and PH (AP: -3.96, ML: +1.8, DV: -8.0 to -8.5) to detect serotonin 
and histaminergic regulation of serotonin respectively. A stainless-steel stimulating 
electrode (diameter: 0.2 mm, Plastics One, Roanoke, VA) was positioned into the MFB 
(for histamine, AP: -1.8, ML: +1.8, DV: −8.0 and for serotonin, AP: -2.40, ML: +1.8, 
DV: -8.0). Biphasic pulse trains were applied through a linear constant current stimulus 
isolator (NL800A, Neurolog, Medical Systems Corp., Great Neck, NY) to provoked 
histamine efflux. The 60 Hz trains were 360 μA each phase, 2 ms in width, and 2 s in 
length. All potentials were measured with respect to a Ag/AgCl reference electrode 
(constructed by plating Cl- ions onto a Ag wire) which was implanted into the brain’s 
opposite hemisphere. 
6.2.4 Data Collection 
A commercially available potentiostat (Dagan Corporation, Minneapolis, MN) 
and a custom built hardware interfacing a PCIe-6341 DAC/ADC card (National 
Instruments, Austin, TX) were used to attain waveform generation, data acquisition, and 
signal processing. Custom built software, written in-house using LabVIEW 2009, was 




signal averaging and digital filtering (Knowmad Technologies LLC, Tucson, AZ). All the 
error bars represent the standard error of the mean (SEM). 
6.3 Results 
6.3.1 Histaminergic Regulation of Serotonin 
 
Figure 7.2. (A & B) Representative color plots of simultaneous detection of evoked 
histamine and ambient serotonin in the posterior hypothalamus of control (F344) and 
HIV-1 Tg rats respectively. Inset in each color plot (white trace) are CVs taken from the 
vertical dashed lines. (C) Top panel - [Histamine] vs. time plots for the control rats (solid 
blue trace) and HIV-1 Tg rats (solid red trace). Bottom panel - [Serotonin] vs. time plots 
comparing control animal (solid blue trace) and HIV-1 Tg (solid red trace). Shaded 
regions in each trace show the standard error of the mean (SEM) for n=7 animals. Green 
bars underneath the color plots denote occurrence and duration of the electrical 
stimulation (2 s) 
In this experiment, we simultaneously detected in vivo histamine and serotonin in 
HIV-1 Tg rats. Figure 7.2 illustrates histaminergic regulation of serotonin in the rat PH. 
Figure 7.2A & B show representative color plots of simultaneous detection of histamine 
and serotonin for control and HIV-1 Tg rats, respectively. Stimulated release of histamine 




Figure 7.2C- top panel. Similarly, inverse regulation of serotonin is also increased in 
HIV-1 Tg rats (red) when compared to the control (blue) as shown in Figure 7.2C. 
6.3.2 Serotonin 
We then positioned the CFM in the prefrontal cortex to detect the stimulated 
release of serotonin. Figure 7.2 A & B illustrate representative color plots of evoked 
serotonin for control and HIV-1 Tg rats, respectively. Stimulated release of serotonin was 
significantly attenuated in HIV-1 Tg rats (red) in comparison to control animals (blue) as 
shown in Figure 7.2 C. 
 
Figure 7.3. (A & B) Representative color plots of the stimulated release of serotonin in 
the prefrontal cortex of control and HIV-1 Tg rats, respectively. Inset in each color plot 
(white trace) shows the typical cyclic voltammogram for serotonin, extracted from the 
vertical dashed line along the event. (C) [Serotonin] vs. time plot comparing control 
(solid blue trace) and HIV-1 Tg rats (solid red trace). Shaded regions in each trace show 
the standard error of the mean (SEM) for n=10 animals. Green bars underneath the color 
plots denote the occurrence and duration of the electrical stimulation (2s) 
6.4 Discussion 
This animal model (HIV-1 Tg rats) expresses seven of the nine genes produced by 
the HIV-1 virus in humans and displays the same symptoms occurring after infection in 




dependent on the Pol protein which is not expressed in the HIV-1 Tg rat. Therefore, 
while the presence of the virus is maintained in the blood, the virus cannot replicate. 
These transgenic rats have been shown to express neurological disorders that mirror HIV 
in humans24,25. In addition, this disease model develops cognitive, motor and behavioral 
anomalies which may be linked to elevated immune activation26-28. Thus, we can safely 
use this model of disease to investigate the histamine and serotonin chemistry underlying 
neuroinflammation. 
Recent studies of HIV in humans proved that the virus enters the central nervous 
system in early stages of the infection through infected macrophages and monocytes29. 
Various HIV-1 glycoprotein gp120 isolates interact with the α- or β-chemokine receptors 
that exist on macrophages/microglia, astrocytes, and neurons15. These infected cells 
secrete THF-α, IL-1β, nitric oxide and quinolinone which are inflammatory markers30. 
These inflammatory mediators are neurotoxic and can potentially lead to 
neuroinflammation. Therefore, apoptosis could occur through direct interaction between 
gp120 and neurons or through the release of neurotoxic factors like inflammatory 
mediators15.  
Microglial cells, the immune cells in the brain, protect the brain from injuries, 
viruses and infections. These immune cells migrate to the infected sites and release 
inflammatory mediators31. Recent studies have shown that histamine modulates 
microglial migration and the release of inflammatory mediators like cytokines32 and nitric 
oxide2. Mast cells also contribute to the innate immune system in both central nervous 
system and peripheral system33. Mast cells can be found in the brain and these cells 




present is considerably lower in healthy organisms than in inflammation states. With 
inflammation, mast cells migrate through BBB36 and release more inflammatory 
mediators like histamine and cytokines37 again suggesting histamine may have a 
significant role in brain diseases which are associated with neuroinflammation. Our 
results also support the hypothesis, as elevated histamine release was observed in HIV-1 
Tg rats when compared to the control animals (Figure 7.1). The recruiting of more mast 
cells into the brain during neuroinflammation and the release of more histamine to 
regulate microglial cells may possibly result in the elevated stimulated release of 
histamine in HIV-1 Tg rats. 
Our own and other studies have shown that H3 receptors regulate serotonin 
release7,9,38. Therefore, it follows that histamine release during neuroinflammation would 
result in enhanced serotonin inhibition. Accordingly, HIV-1 Tg rats demonstrated greater 
inhibition of serotonin (Figure 7.1). This observation was also reflected in the stimulated 
release of serotonin in PFC (Figure 7.2). Moreover, impaired serotonin levels have been 
implicated in many brain disorders like depression and neurodegeneration, which are also 
comorbid with neuroinflammation39-42. Collectively, histamine may have a significant 
impact in controlling the serotonin release during brain diseases that also exhibit 
increased neuroinflammation.  
In summary, we have illustrated that our novel electrochemical method can be 
used to investigate real-time in vivo histaminergic regulation of serotonin in disease or 
pathophysiological states. The fundamental neurochemical information gained from this 




pharmacological, animal model, and behavior experiments are necessary to further 
establish this hypothesis. 
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CONCLUSIONS AND PROSPECTS 
Histamine and serotonin are important biogenic amines that regulate a variety of 
brain functions. These two chemical messengers are thought to modulate each other, but 
their fundamental neuromodulation mechanisms are not well understood, making such 
brain disorders difficult to diagnose and treat. However, studying the underlying 
neurochemistry of histamine and serotonin has been challenging due to the absence of 
suitable analytical techniques. This dissertation introduced a systematic approach to 
overcome this challenge.  
 In this dissertation, I first used Cu(II) metal analysis to understand the adsorption 
driven FSCV response. We described that adsorption of Cu(II) onto CFMs follows a 
monolayer Langmuir adsorption isotherm. I then used the adsorption phenomenon to 
established a novel FSCV method to selectively and sensitively monitor histamine 
neurotransmission in the mouse PH. In this method, electrically evoked histamine was 
measured in the PH upon stimulation in the MFB. This work was extended to 
simultaneously monitor in vivo histamine and serotonin in real time. This work revealed 
that histamine potently inhibits serotonin in a concentration dependent manner, 
highlighting histamine’s roles in regulating serotonin release in the brain. Additionally, 
pharmacological and mathematical models proved that this inhibitory mechanism is 




histamine’s reuptake mechanism via monoamine transporter proteins by pharmacological 
manipulations. I demonstrated that the histamine uptake mechanism is mediated by OCT. 
Interestingly, the histamine reuptake mechanism was also inhibited by escitalopram and 
citalopram which are commercially available antidepressant drugs. Transporter inhibitory 
drugs elevate extracellular serotonin, which is in turn inhibited by increased histamine via 
H3 receptors. Finally, I utilized FSCV to measure serotonin and histamine 
neurotransmissions in HIV-1 Tg rats, which display neuroinflammation, to investigate 
neurochemical changes in the disease state. In this study, both stimulated release of 
histamine and inverse regulation of serotonin were enhanced in HIV-1 Tg rats when 
compared to the control animals.   
Future studies will be required for the in-depth understanding of fundamental 
neurochemical changes that happen during neuroinflammation. The preliminary 
observations that we obtained with HIV-1 Tg rats (chapter 6) suggest that histamine plays 
a vital role in inversely regulating serotonin release in the brain during 
neuroinflammation. Since neuroinflammation is comorbid with various brain disorders 
like depression, more pharmacological, animal model, and behavior experiments are 
necessary to establish the histamine hypothesis. 
In chapter 4, we illustrated the simplest version of the mathematical model, which 
explains the FSCV response related to fundamental physiological functions for histamine 
and serotonin. More experiments are required to expand this original mathematical model 
with the ultimate goal of applying the model in brain diseases. This goal can be achieved 
by pharmacological manipulations of histamine and serotonin neurochemistry. This 




neurochemistry during any disease state, and this information can be subsequently used 
to develop more effective therapies and drugs for histamine and serotonin related brain 
disorders.  
Collectively, this dissertation showcased a novel, powerful FSCV method for 
simultaneous detection of in vivo histamine and serotonin in real time. The advancement 
of this approach facilitates the systematic study of the histaminergic modulation of 
serotonin in a variety of neurochemical processes and brain diseases, stressing the 
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